Questions about Rheumatoid Arthritis? Get answers from our expert.

Cyclosporine

Pronunciation

Class: Immunosuppressive Agents
VA Class: IM600
Chemical Name: Cyclosporin A
Molecular Formula: C62H111N11O12
CAS Number: 59865-13-3
Brands: Gengraf, Neoral, Sandimmune

Warning(s)

  • Supervising Clinician and Medical Resources
  • Only clinicians experienced in management of systemic immunosuppressive therapy for the indicated disease and/or management of organ transplant patients should prescribe cyclosporine.476 477 478 479

  • Patients should be managed in facilities with adequate laboratory and supportive medical resources; the clinician responsible for maintenance therapy should have complete information for patient follow-up.476 477 478 479

  • Effects of Immunosuppression
  • Immunosuppression may result in increased susceptibility to infection and possible development of lymphoma or other neoplasms.476 477 478 595 (See Lymphomas and Other Malignancies under Cautions.)

  • Manufacturer cautions that conventional (nonmodified) oral formulations and the concentrate for injection should be administered with corticosteroids but not with other immunosuppressive agents in organ transplant recipients.479 Manufacturers state that modified oral formulations of cyclosporine (Neoral and Gengraf) may be administered with oral immunosuppressive agents in transplant patients, although the degree of immunosuppression produced may result in increased susceptibility to infection and possible development of lymphoma and other neoplasms.476 477 478 594

  • Bioequivalency of Formulations
  • Conventional (nonmodified) oral formulations (Sandimmune liquid-filled capsules and solution) have decreased bioavailability compared with modified oral formulations (Neoral and Gengraf liquid-filled capsules and solution).476 477 478 479 Conventional (nonmodified) and modified formulations are not bioequivalent and cannot be used interchangeably without physician supervision.476 477 478 479 (See Conversion from Conventional Oral Formulations [Sandimmune] to Modified Oral Formulations [Gengraf, Neoral] under Dosage and Administration.)

  • Absorption of cyclosporine during chronic administration of Sandimmune capsules and oral solution may be erratic.479 Patients, especially liver transplant recipients, receiving these formulations over a period of time should be monitored at repeated intervals for blood cyclosporine concentrations and possible organ rejection due to low absorption of cyclosporine.479

  • For a given trough concentration, cyclosporine exposure will be greater with Neoral or Gengraf preparations than with Sandimmune preparations.476 477 478 Exercise particular caution if a patient is receiving exceptionally high doses of Sandimmune and is converted to Gengraf or Neoral.476 477 478 (See Conversion from Conventional Oral Formulations [Sandimmune] to Modified Oral Formulations [Gengraf, Neoral] under Dosage and Administration.)

  • Patients receiving Gengraf or Neoral liquid-filled capsules or oral solution for organ transplant or in the management of rheumatoid arthritis should also have blood cyclosporine concentrations monitored to avoid toxicity due to high concentrations.476 477 478 (See Monitoring of Cyclosporine Concentrations under Cautions.)

  • Psoriasis Patients
  • Previous therapy with psoralen and UVA light (PUVA) and, to a lesser extent, methotrexate, other immunosuppressive agents, UVB, coal tar, or radiation therapy may increase risk of skin malignancies in patients receiving cyclosporine.476 477 478

  • Recommended dosages can cause hypertension and nephrotoxicity; risk increases with dose and duration of therapy.476 477 478 Monitor renal function (see General: Psoriasis, under Dosage and Administration).476 477 478

Introduction

Immunosuppressive agent and disease-modifying antirheumatic drug (DMARD);1 2 31 65 cyclic polypeptide.478 479

Uses for Cyclosporine

Renal, Hepatic, and Cardiac Allotransplantation

Prevention of allograft rejection in kidney,1 2 9 11 16 22 68 69 liver,1 2 23 35 or heart transplant patients.1 2 18 36

Treatment of chronic allograft rejection in patients previously treated with other immunosuppressive agents (e.g., azathioprine).1

Manufacturers state that corticosteroid therapy should be used concomitantly with IV cyclosporine1 170 and conventional (nonmodified) oral formulations (Sandimmune)170 and be administered concomitantly, at least initially, with modified oral formulations (Gengraf or Neoral).391 476 477 Alternatively, some clinicians believe that routine concomitant use of corticosteroids during cyclosporine therapy is not necessary and that their use should be reserved for acute periods of allograft rejection.9 11 22

Slideshow: Psoriasis: Treatment Options to Manage Your Symptoms

Bone Marrow Allotransplantation

Prevention of acute graft-vs-host disease following bone marrow transplantation.2 19 25 26 97 98 99 100

Has been used for the treatment of moderate to severe, acute graft-vs-host disease following bone marrow transplantation.24 101 102

Rheumatoid Arthritis

Management of the active stage of severe rheumatoid arthritis in selected adults who have an inadequate response to methotrexate; may be used in combination with methotrexate in those who do not respond adequately to methotrexate monotherapy.367 368 369 370 371 372 373 374 375 376 431

Treatment of rheumatoid arthritis in adults who had an insufficient response to or did not tolerate NSAIAs and other DMARDs.367 369 373 374 375 376

Psoriasis

Treatment of immunocompetent adults with severe (i.e., extensive and/or disabling), recalcitrant plaque psoriasis that is not adequately responsive to ≥1 systemic therapy (e.g., retinoids, methotrexate, PUVA) or in patients for whom other systemic therapy is contraindicated or cannot be tolerated.28 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 431

Crohn’s Disease

Has been used with some success in the management of refractory inflammatory,484 492 fistulizing,484 486 489 and chronically active Crohn’s disease.199 210 211 397 407 484 485 487 492

Cyclosporine Dosage and Administration

General

Transplant Patients

  • Patients should be managed using a center experienced in the use and interpretation of cyclosporine concentrations and their application to dosage adjustment;424 however, if management with such a center is not possible, consult specialized references for general monitoring and dosing guidelines.424

  • Frequency of monitoring blood cyclosporine concentrations depends in part on the time that has elapsed since transplantation, intercurrent illness, and concomitant drugs.424 Monitor concentrations whenever clinical manifestations suggest that dosage adjustment might be necessary.9 424

  • Some clinicians monitor cyclosporine concentrations frequently (e.g., 3 or 4 times weekly to daily) during the early posttransplantation period, reducing monitoring to once monthly by 6–12 months after transplantation.9 424 (See Monitoring of Cyclosporine Concentrations under Cautions.)

Rheumatoid Arthritis

  • Therapeutic response generally is apparent after 4–8 weeks of cyclosporine therapy.431 If benefit is not apparent by week 16, discontinue the drug.431

  • Prior to initiation of cyclosporine therapy, perform careful physical examination of the patient, including measurement of BP on ≥2 occasions and determination of Scr twice for a baseline.431 464

  • Monitor BP and Scr every 2 weeks during the first 3 months of therapy; thereafter, monitor BP and Scr monthly in stable patients.431 Always monitor Scr and BP following modification of concomitant NSAIA therapy, either an increase in dosage and initiation of new NSAIA.431

  • Monitor CBC and liver function at least monthly in patients receiving cyclosporine and methotrexate concomitantly.452

  • Limited experience with long-term cyclosporine therapy for rheumatoid arthritis.431 Following discontinuance of the drug, control of the disease usually wanes within 4 weeks.431

Psoriasis

  • Some improvement in clinical manifestations generally is observed after 2 weeks.431 Satisfactory control and stabilization of psoriasis may require 12–16 weeks of therapy.431

  • Prior to initiation of cyclosporine therapy, perform careful dermatologic and physical examination of the patient, including measurement of BP on ≥2 occasions.431 458 Obtain baseline measurements for Scr (on 2 occasions), BUN, CBC, and serum concentrations of magnesium, potassium, uric acid, and lipids.431

  • Evaluate BP every 2 weeks during the first 3 months of therapy; thereafter, evaluate BP monthly in stable patients or more frequently if dosage is adjusted.431

  • Monitor Scr and BUN every 2 weeks during the first 3 months of therapy; thereafter, monitor these values monthly in stable patients.431

  • Monitor CBC and serum concentrations of magnesium, potassium, uric acid, and lipids every 2 weeks during the first 3 months of therapy; thereafter, monitor these values monthly in stable patients or more frequently if dosage is adjusted.431

  • Discontinuance generally results in relapse within several weeks.431

Administration

Administer orally as conventional (nonmodified) or modified formulations or by IV infusion.407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 476 477 478 479 483

Oral Administration

Modified formulations of cyclosporine (Gengraf, Neoral), both as the solution and in the liquid-filled capsules, have increased oral bioavailability compared with the conventional oral solution and liquid-filled capsules of the drug (Sandimmune); conventional (nonmodified) and modified formulations are not bioequivalent.476 477 478 479 (See Pharmacokinetics.) Any change in the formulation of cyclosporine should be performed with caution and under the supervision of a clinician since dosage adjustment may be necessary.476 477 478 479

Conventional (nonmodified) capsules of Sandimmune are bioequivalent to Sandimmune oral solution.479

Modified oral capsules of Neoral are bioequivalent to Neoral oral solution.478 Modified oral capsules of Gengraf are bioequivalent to Gengraf oral solution.476 477 The Neoral and Gengraf modified oral formulations are bioequivalent to each other.480 481 482

Conventional (Nonmodified) Capsules (Sandimmune)

Administer orally once daily on a consistent schedule with regard to time of day and in relation to meals.170 171

Modified Capsules (Gengraf and Neoral)

Administer orally twice daily on a consistent schedule with regard to time of day and in relation to meals.391 476

Conventional (Nonmodified) Oral Solution (Sandimmune)

Administer orally once daily on a consistent schedule with regard to time of day and in relation to meals.170 171

Measure dose carefully2 with the graduated dosing syringe provided by the manufacturer.1 Remove the protective cover of the dosing syringe and withdraw the prescribed dose from the bottle and transfer to a glass (not plastic) container of suitable beverage.1 107 391 Use of a glass container may minimize adherence of the drug to the container walls.1 2 107 170 391 Do not use styrofoam containers; they are porous and may absorb the drug.107 170 391

To increase palatability, mix the measured dose with milk, chocolate milk, or orange juice, preferably at room temperature but not hot.1 107 Avoid frequent changing of the diluting beverage.170 Stir well and administer immediately.1 170 391 After the initial diluted solution has been administered, rinse the container with additional diluent (e.g., juice) and administer the remaining mixture to ensure that the entire dose has been given.1 107

After use, dry the outside of the dosing syringe with a clean, dry towel and replace the protective cover.1 107 Do not rinse the dosing syringe with water, alcohol, or other cleaning agents.1 107 If the syringe requires cleaning, allow it to dry completely before reuse, since introduction of water into the product will cause variation in dose.170

Modified Oral Solution (Gengraf and Neoral)

Administer orally twice daily on a consistent schedule with regard to time of day and in relation to meals.391 477

Prepare and administer Gengraf or Neoral modified oral solution in a similar manner to the conventional (nonmodified) oral solution;391 however, the dosing syringe for Gengraf does not have a protective cover.477

To increase palatability, mix the measured dose with orange or apple juice at room temperature;391 477 do not use milk for dilution, since the resultant mixture can be unpalatable.391 477

After use of Gengraf oral solution, dry the outside of the dosing syringe with a clean towel and store the syringe in a clean, dry place.477

IV Administration

For solution and drug compatibility information, see Compatibility under Stability.

Reserve IV administration for patients in whom oral administration is not tolerated or is contraindicated (due to risk of anaphylaxis with IV administration).1 170

Switch patients to an oral formulation as soon as possible after surgery.1 170

Cyclosporine concentrate for injection must be diluted prior to IV infusion.1 170

Dilution

Dilute each mL of the injection concentrate in 20–100 mL of 0.9% sodium chloride or 5% dextrose injection immediately before administration.1 170 (See Parenteral under Storage.)

Rate of Administration

Transplant patients: Infuse over 2–6 hours.1 170

Crohn’s disease: Infuse over 24 hours.492

Dosage

Individualize dosage of cyclosporine.2 9 170 391 424 425 476 477

Pediatric Patients

Transplant Recipients
Conventional Capsules and Oral Solution (Sandimmune)
Oral

Initially, 15 mg/kg administered as a single dose 4–12 hours before transplantation.1 9 Lower initial dosages (e.g., 10–14 mg/kg daily) may be preferred for renal allotransplantation.170

Postoperatively, continue initial dosage once daily for 1–2 weeks; then, taper by 5% per week (over about 6–8 weeks) to a maintenance dosage of 5–10 mg/kg daily.1 9 170 Maintenance dosages have been tapered to as low as 3 mg/kg daily in selected renal allograft recipients without an apparent increase in graft rejection rate.1 133 170

In several studies, pediatric patients have required and tolerated higher dosages.1 170

Modified Capsules and Oral Solution (Gengraf and Neoral)
Oral

Newly transplanted patients may receive the modified oral formulation at the same initial dose as for the conventional (nonmodified) oral formulation.391 476 477

Suggested initial dosages (based on a 1994 survey of average dosages of conventional formulations): 9 mg/kg for renal allograft recipients, 8 mg/kg for hepatic allograft recipients, and 7 mg/kg for cardiac allograft recipients administered in 2 equally divided doses daily.391 Give initial dose 4–12 hours before transplantation or postoperatively.391 476 477

Adjust dosage to attain a predefined blood cyclosporine concentration.391 476 477 Titrate dosage based on clinical evaluation of rejection and patient tolerability.391 476 477 Lower maintenance dosages may be possible with modified oral formulations compared with conventional (nonmodified) formulations.391 476 477

Conversion from Conventional Oral Formulations (Sandimmune) to Modified Oral Formulations (Gengraf, Neoral)
Oral

Initial dosage of the modified formulation should be the same as the previous dosage of the conventional (nonmodified) oral formulation (1:1 conversion).391 476 477 Adjust dosage to attain trough blood concentrations that are similar to those achieved with the conventional oral formulation; however, attainment of therapeutic trough concentrations will result in greater exposure (AUC) to cyclosporine than would occur with the conventional oral formulation.391 476 477

Monitor trough blood cyclosporine concentrations every 4–7 days until they are the same as they were with the conventional (nonmodified) oral formulation.391 476 477 Monitor patient safety by determining Scr and BP every 2 weeks for the first 2 months after the conversion.391 476 477 Adjust dosage if trough blood concentrations are outside of the desired range and/or measures of safety worsen.391 476 477 Dosage titration should be guided by trough blood concentrations, tolerability, and clinical response.391 476 477

Monitor trough blood concentrations closely following conversion from conventional (nonmodified) oral formulations to modified oral formulations in patients with suspected poor absorption of cyclosporine from the conventional formulations.391 476 477 Measure trough blood concentrations in these patients at least twice weekly (daily in patients receiving >10 mg/kg daily) until the trough blood cyclosporine concentration is maintained in the desired range, since higher bioavailability from the modified oral formulations may result in excessive trough concentrations after conversion to this formulation.391 476 477 Use caution with conversional dosages >10 mg/kg daily.391 476 477

Concentrate for Injection
IV

Initially, 5–6 mg/kg as a single dose 4–12 hours before transplantation.1 170 Postoperatively, 5–6 mg/kg once daily until the patient is able to tolerate oral administration.1 170 Pediatric patients may require higher dosages.170

In patients unable to take cyclosporine orally, may administer the drug by IV infusion at about one-third the recommended oral dosage.1 170

Adults

Transplant Recipients
Conventional Capsules and Oral Solution (Sandimmune)
Oral

Initially, 15 mg/kg administered as a single dose 4–12 hours before transplantation.1 9 Lower initial dosages (e.g., 10–14 mg/kg daily) may be preferred for renal allotransplantation.170

Postoperatively, continue initial dosage once daily for 1–2 weeks; then, taper by 5% per week (over about 6–8 weeks) to a maintenance dosage of 5–10 mg/kg daily.1 9 170 Maintenance dosages have been tapered to as low as 3 mg/kg daily in selected renal allograft recipients without an apparent increase in graft rejection rate.1 133 170

Modified Capsules and Oral Solution (Gengrafand Neoral)
Oral

Newly transplanted patients may receive the modified oral formulation at the same initial dose as for the conventional (nonmodified) oral formulation.391 476 477

Suggested initial dosages (based on a 1994 survey of average dosages of conventional formulations): 9 mg/kg for renal allograft recipients, 8 mg/kg for hepatic allograft recipients, and 7 mg/kg for cardiac allograft recipients administered in 2 equally divided doses daily.391 476 477 Give initial dose 4–12 hours before transplantation or postoperatively.391 476 477

Adjust dosage to attain a predefined blood cyclosporine concentration.391 476 477 Titrate dosage based on clinical evaluation of rejection and patient tolerability.391 476 477 Lower maintenance dosages may be possible with modified oral formulations compared with conventional (nonmodified) formulations.391 476 477

Conversion from Conventional Oral Formulations (Sandimmune) to Modified Oral Formulations (Gengraf, Neoral)
Oral

Initial dosage of the modified oral formulation should be the same as the previous dosage of the conventional (nonmodified) oral formulation (1:1 conversion).391 476 477 Adjust dosage to attain trough blood concentrations that are similar to those achieved with the conventional oral formulation; however, attainment of therapeutic trough concentrations will result in greater exposure (AUC) to cyclosporine than would occur with conventional oral formulation.391 476 477

Monitor trough blood cyclosporine concentrations every 4–7 days until they are the same as they were with the conventional (nonmodified) oral formulation.391 476 477 Monitor patient safety by determining Scr and BP every 2 weeks for the first 2 months after the conversion.391 476 477 Adjust dosage if trough blood concentrations are outside of the desired range and/or measures of safety worsen.391 476 477 Dosage titration should be guided by trough blood concentrations, tolerability, and clinical response.391 476 477

Monitor trough blood concentrations closely following conversion from conventional (nonmodified) oral formulations to modified oral formulations in patients with suspected poor absorption of cyclosporine from the conventional formulations.391 476 477 Measure trough blood concentrations in these patients at least twice weekly (daily in patients receiving >10 mg/kg daily) until the trough blood cyclosporine concentration is maintained in the desired range, since higher bioavailability from the modified oral formulations may result in excessive trough concentrations after conversion to this formulation.391 476 477 Use caution with conversional dosages >10 mg/kg daily.391 476 477

Concentrate for Injection
IV

Initially, 5–6 mg/kg as a single dose 4–12 hours before transplantation.1 170 Postoperatively, 5–6 mg/kg once daily until the patient is able to tolerate oral administration.1 170

In patients unable to take cyclosporine orally, may administer the drug by IV infusion at about one-third the recommended oral dosage.1 170

Rheumatoid Arthritis
Modified Capsules and Oral Solution (Gengraf and Neoral)
Oral

Initially, 2.5 mg/kg daily in 2 divided doses.431 476 477 If response is insufficient but tolerance to the drug is good (including Scr <30% above baseline), may increase dosage by 0.5–0.75 mg/kg daily after 8 weeks and, again, after 12 weeks (maximum 4 mg/kg daily).431 476 477

Reduce dosage by 25–50% to control adverse effects (e.g., hypertension, clinically important laboratory abnormalities) that occur.431 476 477 Manage persistent hypertension by further reduction of cyclosporine dosage or use of antihypertensive agents.431 476 477 Discontinue if adverse effects are severe or do not respond to dosage reduction.431 476 477

Psoriasis
Modified Capsules and Oral Solution (Gengraf and Neoral)
Oral

Initially, 1.25 mg/kg twice daily.431 458 476 477 Continue for ≥4 weeks unless prohibited by adverse effects.431 476 477 If initial dosage does not produce substantial clinical improvement within 4 weeks, increase dosage by approximately 0.5 mg/kg daily once every 2 weeks (maximum 4 mg/kg daily) based on the patient’s tolerance and response.431 476 477

Use lowest dosage that maintains an adequate response (not necessarily total clearance of psoriasis).431 458 476 477 Dosages <2.5 mg/kg daily may be equally effective.431 476 477

Decrease dosage by 25–50% to control adverse effects (e.g., hypertension, clinically important laboratory test abnormalities) that occur.431 476 477 Discontinue if adverse effects are severe or do not respond to dosage reduction.431 476 477

Crohn’s Disease
Conventional (Nonmodified) Capsules (Sandimmune)
Oral

3.8–8 mg/kg daily has been used.492

Concentrate for Injection
IV

Initially, 4 mg/kg daily for about 2–10 days has been used.492 Patients who respond to initial IV regimen may be switched to oral therapy.492

Prescribing Limits

Adults

Rheumatoid Arthritis
Modified Capsules and Oral Solution (Gengraf and Neoral)
Oral

Maximum 4 mg/kg daily.431 476 477

Psoriasis
Modified Capsules and Oral Solution (Gengraf and Neoral)
Oral

Maximum 4 mg/kg daily.431 476 477

Special Populations

Renal Impairment

Monitor renal function closely; frequent dosage adjustments may be necessary.476 477 478 479

Contraindicated in rheumatoid arthritis or psoriasis patients with abnormal renal function.431 476 477

Cautions for Cyclosporine

Contraindications

  • Known hypersensitivity to cyclosporine or to any ingredient in the formulation.1 170 391 476 477

  • Rheumatoid arthritis or psoriasis patients with abnormal renal function, uncontrolled hypertension, or malignancies.431 476 477

  • Concurrent therapy with methotrexate or other immunosuppressive agents, coal tar, PUVA, UVB, or other radiation in the management of psoriasis.431 476 477

Warnings/Precautions

Warnings

Renal Effects

Possible nephrotoxicity;1 2 129 elevations of BUN and Scr appear to be dose related, may be associated with high trough concentrations of the drug, and usually are reversible upon discontinuance of the drug.1 3 9 76

In patients with psoriasis, nephrotoxicity may occur at recommended dosages, with increasing risk as dosage and duration of therapy increase.431

Risk of nephrotoxicity may be increased in patients receiving other potentially nephrotoxic agents.1 (See Interactions.)

Monitor renal function carefully.431 Potential for structural kidney damage and permanent renal dysfunction in the absence of appropriate monitoring and dosage adjustment.478

Carefully evaluate renal allograft recipients who develop increased BUN and Scr before adjusting cyclosporine dosage; these increases do not necessarily indicate the occurrence of organ rejection.1 170 391 If elevations of BUN and Scr are persistently high and unresponsive to adjustment of cyclosporine dosage, consider switching to other immunosuppressive therapy.1 170 391 If severe, intractable renal allograft rejection occurs and does not respond to rescue therapy with corticosteroids and monoclonal antibodies, it may be preferable to switch to alternative immunosuppressive therapy391 or to allow the kidney to be rejected and removed rather than to increase the cyclosporine dosage to an excessive level in an attempt to reverse the rejection episode.1 170 391

Possible hyperkalemia2 11 88 129 132 143 167 (may be associated with hyperchloremic metabolic acidosis),170 391 hypomagnesemia,132 136 144 145 decreased serum bicarbonate concentration,2 11 and hyperuricemia.2 11 132 134 146 147 148 149 170 391

Monitoring of Cyclosporine Concentrations

Results obtained with various assay methods and biologic fluids (blood versus plasma or serum) are not interchangeable;10 47 67 76 85 87 425 consult specialized references and/or the assay manufacturer’s labeling for interpretative guidelines.170 391 424

Monitor trough (predose) cyclosporine concentrations.391 424 Standardize the sampling time for each patient; consider the effect of once- versus twice-daily dosing and the time for pharmacokinetic reequilibration to steady state following dosage changes.424

Monitor predose cyclosporine concentrations periodically in patients receiving conventional (nonmodified) oral formulations (Sandimmune capsules or solution), since absorption is reportedly erratic during long-term therapy.1 170 171 424

Monitoring may be especially important in hepatic allograft recipients,1 170 since absorption of the drug in these patients may be erratic, especially during the first few weeks following transplantation (because of surgical techniques [e.g., bile duct management] or surgically induced liver dysfunction).12

Routinely monitor blood or plasma concentrations in allograft recipients receiving the modified oral formulations (Gengraf, Neoral) and periodically in patients with rheumatoid arthritis being treated with these preparations (to avoid toxicity secondary to high cyclosporine concentrations).431 476 477 In studies in psoriasis patients, cyclosporine concentrations did not correlate well with clinical improvement or adverse effects.478

Monitor cyclosporine concentrations carefully following conversion from conventional (nonmodified) oral formulations to modified formulations.391 476 477 (See Conversion from Conventional Oral Formulations [Sandimmune] to Modified Oral Formulations [Gengraf, Neoral)] under Dosage and Administration.)

Adjust dosage to avoid toxicity resulting from high blood or plasma concentrations of the drug or to prevent possible organ rejection resulting from low concentrations.1 170 391 424

Hepatic Effects

Hepatotoxicity reported in patients with kidney, heart, or liver allografts, usually during the first month of therapy when higher dosages are used.1 16 Usually reversible following dosage reduction.1 16

Lymphomas and Other Malignancies

Possible increased development of lymphoma.1 170 391

Manufacturer cautions that although cyclosporine should be administered with corticosteroids, conventional (nonmodified) oral formulations of the drug (Sandimmune) and the concentrate for injection should not be administered concomitantly with other immunosuppressive agents, since increased risk of lymphoma may result.1 170 However, the manufacturers state that modified oral formulations of cyclosporine (Gengraf and Neoral) may be administered with other immunosuppressive agents, although the degree of immunosuppression produced may result in an increased risk of lymphoma and other neoplasms.476 477 478

Evaluate patients thoroughly for the presence of malignancies before initiating cyclosporine therapy for rheumatoid arthritis, as well as during the treatment course.431 Concurrent use of cyclosporine and other immunosuppressive agents may increase the risk of malignancies through induction of excessive immunosuppression.431

Possible increased risk of developing malignancies of the skin and lymphoproliferative disorders in patients receiving cyclosporine to treat psoriasis.431 Evaluate such patients thoroughly before initiating cyclosporine therapy, as well as during the treatment course, for the presence of malignancies; consider that psoriatic plaques may obscure malignant lesions.431 Avoid concomitant therapy with methotrexate or other immunosuppressive agents, coal tar, PUVA, UVB, or other radiation, due to potential for excessive immunosuppression and increased risk of malignancies.431 Limit exposure to sunlight or other UV light during cyclosporine therapy.476 477 478

Infectious Complications

Possible increased susceptibility to infection.1 170 391

Evaluate psoriasis patients for presence of occult infection prior to and throughout therapy.478

Manufacturer cautions that although cyclosporine should be administered with corticosteroids, conventional (nonmodified) oral formulations of the drug (Sandimmune) and the concentrate for injection should not be administered concomitantly with other immunosuppressive agents, since increased susceptibility to infection may result.1 170 However, the manufacturers state that modified oral formulations (Gengraf and Neoral) may be administered with other immunosuppressives, although the degree of immunosuppression produced may result in increased susceptibility to infection.476 477 478

Latent Viral Infections

Increased risk of reactivation of latent viral infections, including BK virus-associated nephropathy (BKVN).584 585 586 587 588 589 590 591 592 594 595 Principally observed in renal transplant patients (usually within the first year posttransplantation); may result in severe allograft dysfunction and/or graft loss.584 585 586 587 588 589 590 591 592 594 595 Risk appears to correlate with degree of overall immunosuppression rather than use of specific immunosuppressant.585 586 587 588 589 590 591 592 Monitor closely for signs of BKVN (e.g., deterioration of renal function);584 585 586 588 594 595 if BKVN develops, institute early treatment, and consider reducing immunosuppressive therapy.584 585 586 587 588 590 591 592 594 595

Bioequivalency of Formulations

Modified oral formulations of cyclosporine (Gengraf and Neoral liquid-filled capsules and solution) have increased oral bioavailability compared with conventional (nonmodified) oral formulations (Sandimmune liquid-filled capsules and solution); therefore, the modified and conventional (nonmodified) formulations are not bioequivalent and cannot be used interchangeably without appropriate medical supervision.476 477 478 479 (See Conversion from Conventional Oral Formulations [Sandimmune] to Modified Oral Formulations [Gengraf, Neoral] under Dosage and Administration.)

For a given trough concentration, cyclosporine exposure will be greater with Gengraf and Neoral preparations than with Sandimmune preparations.476 477 478

Conversion from Gengraf or Neoral to Sandimmune preparations using a 1:1 ratio may result in lower blood concentrations; increase monitoring to avoid the potential of underdosing.476 477 478 479

Hematologic Effects

Possible leukopenia, anemia, and thrombocytopenia.1

Risk of developing syndrome of thrombocytopenia and microangiopathic hemolytic anemia1 170 337 338 339 340 391 (pathologically similar to hemolytic uremic syndrome); may result in graft failure.431 Manifestations include thrombosis of renal microvasculature with platelet-fibrin thrombi occluding glomerular capillaries and afferent arterioles, microangiopathic hemolytic anemia, thrombocytopenia, and decreased renal function.170 337 338 339 340 391 Such findings are generalizable to other immunosuppressive agents used after transplantation.170 391 Neither the pathogenesis nor optimal management is clear.1 391

CNS Effects

Potential for seizures, particularly when used in combination with high-dose corticosteroids.1 104 105 106 107 129 130 131 138 170 391

Encephalopathy, manifested by impaired consciousness, seizures, visual changes (e.g., blindness), loss of motor function, movement disorders, and psychiatric disturbances, described in patients receiving cyclosporine; in many cases, such manifestations accompanied by white-matter changes.476 477 478 479 May be associated with high blood or plasma concentrations of the drug,138 153 161 162 163 164 165 476 477 478 479 concurrent high-dose corticosteroid therapy,1 129 130 131 153 154 476 477 478 479 hypertension,70 74 129 150 153 164 165 476 477 478 479 and/or hypomagnesemia.106 129 130 131 132 138 144 145 153 155 476 477 478 479 May be reversible upon discontinuance of the drug or following dosage reduction.476 477 478 479

Optic disc edema with possible visual impairment reported rarely; occurred more frequently in transplant recipients.476 477 478 479

Sensitivity Reactions

Anaphylaxis

Risk of anaphylaxis with IV cyclosporine; reserve for patients unable to tolerate oral formulations of the drug.1 170

Continuously observe patients for ≥30 minutes following initiation of the IV infusion; closely monitor at frequent intervals thereafter for possible allergic manifestations.1 170 Appropriate equipment for maintenance of an adequate airway and other supportive measures and agents for the treatment of anaphylactic reactions (e.g., epinephrine, oxygen) should be readily available.1 170

If anaphylaxis occurs, discontinue IV infusion immediately and administer appropriate therapy (e.g., epinephrine, oxygen) as indicated.1 170

General Precautions

Hypertension

Mild to moderate hypertension occurs in about 50% of renal transplant recipients and most cardiac transplant patients receiving the drug.1 Hypertension reported in about 28% of psoriasis patients and systolic hypertension reported in about 33% of rheumatoid arthritis patients receiving the drug.431

Generally develops within a few weeks after beginning cyclosporine therapy129 132 150 151 152 156 157 159 160 167 and affects both SBP and DBP.132 167

May respond to dosage reduction and/or antihypertensive therapy,107 but response to antihypertensive therapy may be variable.132 150 151 152 156 160 Elevated DBP may be more resistant to treatment than elevated SBP.129 132 149 156

Contraindicated in rheumatoid arthritis and psoriasis patients with uncontrolled hypertension.478

Malabsorption Syndromes

Patients with malabsorption may have difficulty achieving therapeutic concentrations of cyclosporine with conventional (nonmodified) oral formulations (Sandimmune).479

Specific Populations

Pregnancy

Category C.478 479

Lactation

Distributed into milk; women should not breast-feed infants while receiving the drug.1 75 170 391 424

Pediatric Use

No adequate and controlled studies to date; however, cyclosporine has been used in children ≥6 months of age without unusual adverse effects.1 170 Modified oral formulations (Gengraf and Neoral) used in children ≥1 year of age.391 476 477

Consider the possibility that serious nephrotoxicity, hypertension, and/or seizures may occur.41 74

Safety and efficacy of cyclosporine for the management of juvenile rheumatoid arthritis or psoriasis in children <18 years of age not established.431 476 477

Geriatric Use

Assess renal function with particular care, due to greater frequency of decreased renal function observed in geriatric patients.431

Patients ≥65 years of age were more likely to develop systolic hypertension while receiving cyclosporine to treat rheumatoid arthritis in clinical studies and also were more likely to have Scr elevations of ≥50% above baseline after 3–4 months of therapy.431

Renal Impairment

Use with caution; assess renal function prior to and periodically during prolonged therapy.478 479 Dosage adjustment may be necessary depending on degree of renal impairment.478 479

Carefully evaluate renal allograft recipients who develop increased BUN and Scr before initiating adjustment of cyclosporine dosage, since these increases do not necessarily indicate the occurrence of organ rejection.1 170 391

Contraindicated in rheumatoid arthritis or psoriasis patients with abnormal renal function.431

Common Adverse Effects

Transplant recipients: Renal impairment, tremor, hirsutism, hypertension, gum hyperplasia.478 479

Rheumatoid arthritis: Renal impairment, hypertension, headache, GI disturbances, hirsutism/hypertrichosis.478

Psoriasis: Renal impairment, headache, hypertension, hypertriglyceridemia, hirsutism/hypertrichosis, paresthesia or hyperesthesia, flu-like symptoms, nausea/vomiting, diarrhea, abdominal discomfort, lethargy, musculoskeletal or joint pain.478

Interactions for Cyclosporine

Extensively metabolized by CYP3A.170 177 179 180 181 182 183 391 424 425 429 430

Drugs Affecting Hepatic Microsomal Enzymes

CYP3A inhibitors: Potential pharmacokinetic interaction (increased cyclosporine concentrations in biologic fluid).170 177 179 180 181 182 183 186 391 429 430

CYP3A inducers: Potential pharmacokinetic interaction (decreased cyclosporine concentrations in biologic fluid).170 391

Nephrotoxic Drugs

Potentiation of renal dysfunction well substantiated; may be related to nephrotoxic potential of the interacting drug or to accumulation of cyclosporine induced by the interacting drug.351 391 594 595 Use with caution.594 595

Specific Drugs and Foods

Drug or Food

Interaction

Comments

ACE inhibitors

Possible hyperkalemia476 477 478 479

Caution advised and control of potassium concentrations recommended476 477 478 479

Allopurinol

Increased plasma or blood concentrations of cyclosporine170 177 179 180 181 182 183 186 391 403 404 429 430 594 595

Monitor concentration of cyclosporine; adjust cyclosporine dosage accordingly170 391 594 595

Amiodarone

Increased plasma or blood concentrations of cyclosporine170 177 179 180 181 182 183 186 429 430 594 595

Monitor concentration of cyclosporine; adjust cyclosporine dosage accordingly170 391 594 595

Aminoglycosides (gentamicin, tobramycin)

Possible additive nephrotoxic effects335 594 595 391

Possible increased risk of acute tubular necrosis in renal allograft recipients308 312

Use with caution594 595

Avoid concomitant use in renal allograft recipients308

Amphotericin B

Possible additive nephrotoxic effects335 594 595

If concomitant therapy is necessary, temporarily withhold cyclosporine until trough serum cyclosporine concentration (determined by RIA) is <150 ng/mL; adjust subsequent dosage accordingly15

Angiotensin II receptor blockers

Possible hyperkalemia476 477 478 479

Caution advised and control of potassium concentrations recommended476 477 478 479

Anticonvulsants (carbamazepine, oxcarbazepine, phenobarbital, phenytoin)

Decreased plasma or blood concentrations of cyclosporine107 117 118 119 303 308 335 476 477 478 594 595

Monitor concentration of cyclosporine; adjust cyclosporine dosage accordingly594 595

Antifungals, azoles (fluconazole, itraconazole, ketoconazole, voriconazole)

Increased plasma or blood concentrations of cyclosporine177 179 180 181 182 183 186 429 430 476 477 478 594 595

Carefully monitor concentration of cyclosporine; adjust cyclosporine dosage accordingly594 595

Bosentan

Decreased plasma concentrations of cyclosporine; increased plasma bosentan concentrations476 477 478 593

Concomitant use contraindicated593

Bromocriptine

Increased plasma or blood concentrations of cyclosporine177 179 180 181 182 183 186 429 430 594 595

Monitor concentration of cyclosporine; adjust cyclosporine dosage accordingly594 595

Calcium-channel blocking agents

Diltiazem, nicardipine, verapamil: Increased plasma or blood concentrations of cyclosporine177 179 180 181 182 183 186 429 430 594 595

Nifedipine: Frequent gingival hyperplasia

Diltiazem, nicardipine, verapamil: Monitor concentration of cyclosporine; adjust cyclosporine dosage accordingly594 595

Ciprofloxacin

Possible additive nephrotoxic effects594 595

Use with caution594 595

Colchicine

Possible additive nephrotoxic effects;476 477 478 479 increased plasma or blood concentrations of cyclosporine170 177 179 180 181 182 183 186 391 429 430

Possible decreased clearance of colchicine increasing the potential for enhanced colchicine toxicity (myopathy, neuropathy)476 477 478 479

Monitor concentration of cyclosporine; adjust cyclosporine dosage accordingly594 595

Monitor closely for colchicine toxicity; adjust colchicine dosage or discontinue drug as indicated476 477 478 479

Contraceptives, oral

Increased plasma or blood concentrations of cyclosporine478 479

Monitor concentration of cyclosporine; adjust cyclosporine dosage accordingly594 595

Corticosteroids (methylprednisolone, prednisolone)

Increased plasma or blood concentrations of cyclosporine;77 177 179 180 181 182 183 186 429 430 594 595 possible decreased clearance of prednisolone;478 479 seizures reported with combined cyclosporine and high-dose corticosteroid therapy1 129 130 131 153 154 170 335 391

Monitor concentration of cyclosporine; adjust cyclosporine dosage accordingly594 595

Co-trimoxazole

Possible additive nephrotoxic effects335 594 595

Use with caution594 595

Danazol

Increased plasma or blood concentrations of cyclosporine177 179 180 181 182 183 186 303 308 334 378 380 429 430 594 595

Monitor concentration of cyclosporine; adjust cyclosporine dosage accordingly594 595

Digoxin

Possible decreased volume of distribution and clearance of digoxin;303 308 310 594 595 digoxin toxicity reported 303 308 310 378 594 595

Monitor closely for digoxin toxicity; adjust digoxin dosage accordingly478 479

Diuretics, potassium-sparing

Possible hyperkalemia1 476 477 594 595

Concomitant use not recommended1 476 477 594 595

Fibric acid derivatives

Possible additive nephrotoxic effects478 479 594 595

Use with caution594 595

Grapefruit juice

Increased oral bioavailability of cyclosporine432 435 438 442 444 445 446 447 453 455 478 479

Avoid concomitant use478 479

Histamine H2-receptor antagonists (cimetidine, ranitidine)

Possible additive nephrotoxic effects335

HIV protease inhibitors (indinavir, nelfinavir, ritonavir, saquinavir)

Possible increased plasma or blood concentrations of cyclosporine177 179 180 181 182 183 186 429 430 594 595

Avoid concomitant use

Use concomitantly with caution594 595

HMG CoA reductase inhibitors (statins)(atorvastatin, fluvastatin, lovastatin, pravastatin, simvastatin)

Decreased clearance of the statin; possible myositis, myolysis, or rhabdomyolysis303 304 305 307 335 594 595

Reduce statin dosage; temporarily withhold or discontinue statin therapy in those with signs/symptoms of myopathy or risk factors predisposing to severe renal injury secondary to rhabdomyolysis594 595

Imatinib

Increased plasma or blood concentrations of cyclosporine594 595

Monitor concentration of cyclosporine; adjust cyclosporine dosage accordingly594 595

Immunosuppressive agents

Increased risk of lymphoma and susceptibility to infection1 9 16 170

Avoid concomitant use of conventional (nonmodified) oral formulations or the concentrate for injection with other immunosuppressive agents (except for corticosteroids)1 9 16 170

Modified oral formulations (Gengraf, Neoral) may be administered with other immunosuppressives, although the degree of immunosuppression produced may result in an increased risk of lymphoma and other neoplasms and in susceptibility to infection391 476 477

Patients with psoriasis should not receive cyclosporine concomitantly with other immunosuppressive agents since excessive immunosuppression may result431

Macrolides (azithromycin, clarithromycin, erythromycin)

Increased plasma or blood concentrations of cyclosporine177 179 180 181 182 183 186 429 430 478 479

Monitor concentration of cyclosporine; adjust cyclosporine dosage accordingly478 479

Melphalan

Possible additive nephrotoxic effects335 594 595

Use with caution594 595

Metoclopramide

Increased plasma or blood concentrations of cyclosporine177 179 180 181 182 183 186 303 378 380 429 430 594 595

Monitor concentration of cyclosporine; adjust cyclosporine dosage accordingly594 595

Methotrexate

Possible increased plasma concentrations of methotrexate and decreased plasma concentrations of 7-hydroxymethotrexate; no apparent effect on blood concentrations of cyclosporine 431 478 479

Initiate cyclosporine at same initial dosage and range of adjustment as when administered alone431

Generally administer modified formulations of cyclosporine (Gengraf, Neoral) at ≤3 mg/kg daily in patients receiving methotrexate ≤15 mg weekly431 476 477

Nafcillin

Decreased plasma or blood concentrations of cyclosporine303 308 594 595

Monitor concentration of cyclosporine; adjust cyclosporine dosage accordingly594 595

NSAIAs (diclofenac, naproxen, sulindac)

Possible additive nephrotoxic effects;335 594 595 possible increased BP and/or serum potassium concentrations308 420 421

Increased diclofenac AUC431 461

Monitor Scr following modification of concomitant NSAIA therapy (increase in NSAIA dosage or initiation of new NSAIA)431

Select diclofenac dosage at lower end of the recommended dosage range431

Octreotide

Decreased plasma or blood concentrations of cyclosporine594 595

Monitor concentration of cyclosporine; adjust cyclosporine dosage accordingly594 595

Orlistat

Decreased absorption of cyclosporine478 479

Avoid concomitant use478 479

Potassium-sparing or -containing drugs

Possible hyperkalemia478 479

Caution advised; control of potassium concentrations recommended476 477 478 479

Quinupristin/dalfopristin

Increased plasma or blood concentrations of cyclosporine177 179 180 181 182 183 186 429 430 594 595

Monitor concentration of cyclosporine; adjust cyclosporine dosage accordingly594 595

Rifabutin

Possible increased metabolism of cyclosporine478 479

Use with caution478 479

Rifampin

Decreased plasma or blood concentrations of cyclosporine113 114 115 116 335 594 595

Monitor concentration of cyclosporine; adjust cyclosporine dosage accordingly594 595

St. John’s wort

Marked decrease in blood concentrations of cyclosporine, resulting in subtherapeutic levels, rejection of transplanted organs, and graft loss476 477 478 479

Avoid concomitant use476 477 478 479

Sirolimus

Increased Scr with concomitant sirolimus and full-dose cyclosporine therapy476 477 478 479

Increased blood sirolimus concentrations with concomitant administration476 477 478 479

Increase in Scr generally is reversible with cyclosporine dosage reduction476 477 478 479

Administer sirolimus 4 hours after cyclosporine to minimize effect on sirolimus concentrations476 477 478 479

Sulfinpyrazone

Decreased plasma or blood concentrations of cyclosporine478 479

Monitor concentration of cyclosporine; adjust cyclosporine dosage accordingly478 479

Tacrolimus

Possible additive nephrotoxic effects335 594 595

Avoid concomitant usea

Terbinafine

Decreased plasma or blood concentrations of cyclosporine478 479

Monitor concentration of cyclosporine; adjust cyclosporine dosage accordingly478 479

Ticlopidine

Decreased plasma or blood concentrations of cyclosporine303 308 335 594 595

Monitor concentration of cyclosporine; adjust cyclosporine dosage accordingly594 595

Vaccines

Possible decreased immune response to vaccination594 595

Avoid administration of live vaccines during cyclosporine therapy335 594 595

Vancomycin

Possible additive nephrotoxic effects335 594 595

Use with caution594 595

Cyclosporine Pharmacokinetics

Absorption

Bioavailability

Variably and incompletely absorbed following oral administration.1 2 170 171 391 Undergoes extensive first-pass metabolism following oral administration.2

Extent of absorption depends on the individual patient, patient population (e.g., transplant type), posttransplantation time (e.g., increasing during the early posttransplantation period in renal transplant recipients), bile flow (micellar absorption of the drug involving bile), GI state (e.g., decreased with diarrhea), and formulation administered.391 425

Peak blood and plasma concentrations are attained about 3.5 hours following oral administration of conventional (nonmodified) formulations.479

Modified oral formulations (Gengraf, Neoral) have greater bioavailability than the conventional (nonmodified) oral formulations (Sandimmune).391 411 412 422 476 477 (See Bioequivalency of Formulations under Cautions.)

Conventional (nonmodified) liquid-filled capsules of Sandimmune are bioequivalent to Sandimmune oral solution.170 171 173

Modified oral capsules of Neoral are bioequivalent to Neoral oral solution.391 407 414 Modified oral capsules of Gengraf are bioequivalent to Gengraf oral solution.476 477 The Neoral and Gengraf modified oral formulations are bioequivalent to each other.480 481 482

Food

Data regarding effect of food on cyclosporine absorption are discordant.391 417 425

Plasma Concentrations

Possible decreased frequency of organ rejection when trough blood concentrations (determined by HPLC) are >100 ng/mL.2

Trough blood or plasma concentrations (i.e., at 24 hours) of 250–800 or 50–300 ng/mL, respectively, (determined by RIA) appear to minimize the frequency of graft rejection and cyclosporine-induced adverse effects.1

Possible association between trough serum concentrations >500 ng/mL (determined by RIA) and cyclosporine-induced nephrotoxicity.9

Distribution

Extent

Widely distributed into body fluids and tissues;1 8 most of drug is distributed outside the blood volume.391

Crosses the placenta75 137 139 425 and is distributed into milk.1 139 425

Plasma Protein Binding

Approximately 90–98% (mainly lipoproteins).1 2 391 425

Elimination

Metabolism

Extensively metabolized in the liver, principally by CYP3A, and less extensively in the GI tract and the kidney to at least 30 metabolites.391 425

Elimination Route

Excreted principally via bile, almost entirely as metabolites; about 6% of a dose excreted in urine.1 170 391 425

Half-life

Biphasic; terminal half-life averages 8.4–27 hours (range: 4–50 hours).1 8 170 391 424 425

Stability

Storage

Oral

Capsules, liquid-filled (nonmodified)

25°C (may be exposed to 15–30°C).479

Oral Solution, Concentrate (nonmodified)

<30°C.479 Do not refrigerate; protect from freezing.479

Discard 2 months after opening.479

Capsules, liquid-filled (modified)

Neoral: 20–25°C.478

Gengraf: 15–30°C.476

Oral Solution (modified)

Neoral: 20–25°C.478 Do not refrigerate.478

Gengraf: 15–30°C.477 Do not refrigerate.477

Formation of gel, light flocculation, or formation of light sediment may occur at <20°C; warm Neoral oral solution to 25°C and Gengraf oral solution to 15–30°C to reverse these changes.477 478

Discard 2 months after opening.477 478

Parenteral

Concentrate for Injection

<30°C; protect from light.479

Polyoxyl 35 castor oil (in cyclosporine injection) can cause leaching of bis(2-ethylhexyl) phthalate (DEHP) from PVC containers.1 Cyclosporine 2 mg/mL is stable for 24 hours in dextrose 5% or sodium chloride 0.9% in glass or PVC containers;94 however, to minimize patient exposure to DEHP, some clinicians suggest that diluted solutions in PVC containers be administered immediately after preparation.95

Compatibility

For information on systemic interactions resulting from concomitant use, see Interactions.

Parenteral

Solution CompatibilityHID

Compatible

Amino acids 5%, dextrose 25%

Dextrose 5% in water

Fat emulsion 10 and 20%, intravenous

Sodium chloride 0.9%

Drug CompatibilityHID
Admixture Compatibility

Compatible

Ciprofloxacin

Incompatible

Magnesium sulfate

Y-Site CompatibilityHID

Compatible

Anidulafungin

Caspofungin acetate

Ceftaroline fosamil

Doripenem

Linezolid

Meropenem

Micafungin sodium

Propofol

Sargramostim

Incompatible

Acyclovir sodium

Amphotericin B cholesteryl sulfate complex

Variable

Mycophenolate mofetil HCl

Telavancin HCl

Actions

  • Inhibits cell-mediated immune responses such as allograft rejection,1 2 3 delayed hypersensitivity (e.g., tuberculin-induced),1 2 3 experimental allergic encephalomyelitis,1 2 3 Freund’s adjuvant-induced arthritis,1 and graft-vs-host disease in animal studies.1 2

  • Exact mechanism(s) of immunosuppressive action not fully elucidated; appears to mainly involve inhibition of lymphocytic proliferation and function.1 2 4 6

  • Produces nephrotoxic effects, which generally appear to be dose dependent and reversible.1 4 (See Renal Effects under Cautions.)

Advice to Patients

  • Risk of hypertension and renal impairment.478 479

  • Necessity of routine laboratory testing (e.g., BUN, Scr, bilirubin, liver enzymes) for assessment of renal and hepatic function.1 170 391

  • Increased risk of neoplasia.1 170 391

  • Necessity of making any change in the cyclosporine formulation under the supervision of a clinician, since dosage adjustment may be necessary and caution should be observed during the transition.391

  • Importance of administering oral cyclosporine on a consistent schedule with regard to time of day and in relation to meals.170 171 391

  • Importance of following manufacturer’s instructions for dilution and administration of conventional (nonmodified) oral solution and modified oral solution.477 478 479

  • Importance of avoiding grapefruit juice during cyclosporine therapy.479

  • For psoriasis patients, importance of appropriate protection from the sun and avoidance of excessive solar exposure.431

  • Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs and dietary or herbal supplements, as well as any concomitant illnesses.478 479

  • Importance of women informing their clinician if they are or plan to become pregnant or plan to breast-feed.478 479

  • Importance of informing patients of other important precautionary information.478 479 (See Cautions.)

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Cyclosporine

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Oral

Capsules, liquid-filled (nonmodified)

25 mg

Sandimmune

Novartis

50 mg

Sandimmune

Novartis

100 mg

Sandimmune

Novartis

Capsules, liquid-filled, for emulsion (modified)

25 mg

Gengraf

Abbott

Neoral

Novartis

100 mg

Gengraf

Abbott

Neoral

Novartis

For emulsion, solution (modified)

100 mg/mL

Gengraf

Abbott

Neoral

Novartis

For solution, concentrate (nonmodified)

100 mg/mL

Sandimmune

Novartis

Parenteral

For injection, concentrate for IV infusion only

50 mg/mL

Sandimmune I.V.

Novartis

Comparative Pricing

This pricing information is subject to change at the sole discretion of DS Pharmacy. This pricing information was updated 02/2014. Actual costs to patients will vary depending on the use of specific retail or mail-order locations and health insurance copays.

CycloSPORINE Modified 100MG Capsules (WATSON LABS): 30/$142.98 or 90/$391.95

CycloSPORINE Modified 100MG/ML Solution (WATSON LABS): 50/$259.99 or 150/$730.01

CycloSPORINE Modified 25MG Capsules (WATSON LABS): 30/$45.99 or 60/$79.97

Gengraf 100MG Capsules (ABBOTT): 60/$315.98 or 180/$939.96

Gengraf 25MG Capsules (ABBOTT): 60/$85.98 or 180/$235.94

Neoral 100MG Capsules (NOVARTIS): 30/$185.98 or 90/$496.00

Neoral 100MG/ML Solution (NOVARTIS): 50/$335.99 or 150/$916.01

Neoral 25MG Capsules (NOVARTIS): 30/$45.98 or 60/$91.97

SandIMMUNE 100MG Capsules (NOVARTIS): 30/$309.98 or 60/$614.96

SandIMMUNE 100MG/ML Solution (NOVARTIS): 50/$496.00 or 150/$1,479.91

SandIMMUNE 25MG Capsules (NOVARTIS): 60/$159.99 or 180/$453.95

SandIMMUNE 50MG/ML Solution (NOVARTIS): 5/$45.99 or 15/$123.97

AHFS DI Essentials. © Copyright, 2004-2014, Selected Revisions June 19, 2013. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.

† Use is not currently included in the labeling approved by the US Food and Drug Administration.

References

1. Sandoz Pharmaceuticals Corporation. Sandimmune (cyclosporine) oral solution and I.V. prescribing information. East Hanover, NJ; 1988 Apr 1.

2. Canafax DM, Ascher NL. Cyclosporine immunosuppression. Clin Pharm. 1983; 2:515-24. [IDIS 178539] [PubMed 6360494]

3. White DJG. Cyclosporin A—clinical pharmacology and therapeutic potential. Drugs. 1982; 24:322-34. [IDIS 160327] [PubMed 6754333]

4. Sheil AGR. Cyclosporin A—a new immune suppressive agent. Med J Aust. 1982; 1:37-9. [IDIS 147348] [PubMed 7038415]

5. Sandoz, Inc. Sandimmune pharmacy fact sheet. East Hanover, NJ; 1983 Nov. SDI DD-4.

6. Borel JF, Feurer C, Magnée C et al. Effects of the new anti-lymphocytic peptide cyclosporin A in animals. Immunology. 1977; 32:1017-25. [PubMed 328380]

7. Shulman H, Striker G, Deeg HJ et al. Nephrotoxicity of cyclosporin A after allogeneic marrow transplantation. N Engl J Med. 1981; 305:1392-5. [IDIS 141143] [PubMed 7029278]

8. Beveridge T, Gratwohl A, Michot F et al. Cyclosporin A: pharmacokinetics after a single dose in man and serum levels after multiple dosing in recipients of allogeneic bone-marrow grafts. Curr Ther Res. 1981; 30:5-18.

9. Merion RM, White DJG, Thiru S et al. Cyclosporine: five years’ experience in cadaveric renal transplantation. N Engl J Med. 1984; 310:148-54. [IDIS 179976] [PubMed 6361559]

10. Burckart GJ. Monitoring cyclosporine therapy. Clin Pharm. 1983; 2:568. [IDIS 178545] [PubMed 6653058]

11. European Multicentre Trial Group. Cyclosporin in cadaveric renal transplantation: one-year follow-up of a multicentre trial. Lancet. 1983; 2:986-9. [IDIS 177744] [PubMed 6138592]

12. White DJG, McNaughton D, Calne RY. Is the monitoring of cyclosporin-A serum levels of clinical value? Transplant Proc. 1983; 15:454-6.

13. Ferguson RM, Sutherland DER, Simmons RL et al. Ketoconazole, cyclosporin metabolism, and renal transplantation. Lancet. 1982; 2:882-3. [IDIS 158221] [PubMed 6126744]

14. Dieperink H, Moller J. Ketoconazole and cyclosporin. Lancet. 1982; 2:1217. [IDIS 161092] [PubMed 6128518]

15. Kennedy MS, Deeg HJ, Siegel M et al. Acute renal toxicity with combined use of amphotericin B and cyclosporine after marrow transplantation. Transplantation. 1983; 35:211-5. [IDIS 175498] [PubMed 6340275]

16. Canadian Multicentre Transplant Study Group. A randomized clinical trial of cyclosporine in cadaveric renal transplantation. N Engl J Med. 1983; 309:809-15. [IDIS 175986] [PubMed 6350878]

17. Anon. Cyclosporine—a new immunosuppressive agent. Med Letter Drugs Ther. 1983; 25:77-8.

18. Beveridge T. Cyclosporin-A: an evaluation of clinical results. Transplant Proc. 1983; 15:433-7.

19. Barrett AJ, Kendra JR, Lucas CF et al. Cyclosporin A as prophylaxis against graft-versus-host disease in 36 patients. BMJ. 1982; 285:162-6. [IDIS 154583] [PubMed 6807391]

20. Nagington J, Gray J. Cyclosporin A immunosuppression, Epstein-Barr antibody, and lymphoma. Lancet. 1980; 1:536-7. [IDIS 111566] [PubMed 6102249]

21. Bird AG, McLachlan SM. Cyclosporin A and Epstein-Barr virus. Lancet. 1980; 2:418. [IDIS 125069] [PubMed 6105533]

22. European Multicentre Trial Group. Cyclosporin A as sole immunosuppressive agent in recipients of kidney allografts from cadaver donors. Lancet. 1982; 2:57-60. [IDIS 153443] [PubMed 6123806]

23. Calne RY, Williams R, Lindop M et al. Improved survival after orthotopic liver grafting. BMJ. 1981; 283:115-8. [PubMed 6789932]

24. Powles RL, Barrett AJ, Clink H et al. Cyclosporin A for the treatment of graft-versus-host disease in man. Lancet. 1978; 2:1327-31. [IDIS 91450] [PubMed 82837]

25. Powles RL, Clink HM, Spence D et al. Cyclosporin A to prevent graft-versus-host disease in man after allogeneic bone-marrow transplantation. Lancet. 1980; 1:327-9. [IDIS 109874] [PubMed 6101787]

26. Gale RP, Kay HEM, Rimm AA et al. Bone-marrow transplantation for acute leukaemia in first remission. Lancet. 1982; 2:1006-9. [PubMed 6127500]

27. Stiller CR, Laupacis A, Dupre J et al. Cyclosporine for treatment of early type I diabetes: preliminary results. N Engl J Med. 1983; 308:1226-7. [IDIS 169883] [PubMed 6341839]

28. Mueller W, Herrmann B. Cyclosporin A for psoriasis. N Engl J Med. 1979; 301:555. [IDIS 100685] [PubMed 460314]

29. Calne RY, Rolles K, White DJG et al. Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers. Lancet. 1979; 2:1033-6. [IDIS 104961] [PubMed 91781]

30. Siegl H, Ryffel B. Effect of cyclosporin on renin-angiotensin-aldosterone system. Lancet. 1982; 2:1274. [PubMed 6128567]

31. Windholz M, ed. The Merck index. 10th ed. Rahway, NJ: Merck & Co, Inc; 1983:396.

32. Thommen-Scott K. Antimalarial activity of cyclosporin A. Agents Actions. 1981; 11:770-3. [PubMed 7041571]

33. Kreis W, Soricelli A. Cyclosporins: immunosuppressive agents with antitumor activity. Experientia. 1979; 35:1506-8. [PubMed 510504]

34. Bueding E, Hawkins J, Cha YN. Antischistosomal effects of cyclosporin A. Agents Actions. 1981; 11:380-3. [PubMed 7282489]

35. Starzl TE, Iwatsuki S, Van Thiel DH et al. Evolution of liver transplantation. Hepatology. 1982; 2:614-36. [PubMed 6749635]

36. Oyer PE, Stinson EB, Jamieson SW et al. Cyclosporine in cardiac transplantation: a 2½ year follow-up. Transplant Proc. 1983; 15(Suppl 1):2546-52. [PubMed 6420962]

37. Davison AN, Ilyas AA. Cyclosporin A inhibits ganglioside-stimulated lymphocyte rosette formation in multiple sclerosis. Int Arch Allergy Appl Immunol. 1982; 69:393-6. [PubMed 7141720]

38. Nussenblatt RB, Palestine AG, Rook AH et al. Treatment of intraocular inflammatory disease with cyclosporin A. Lancet. 1983; 2:235-8. [IDIS 173801] [PubMed 6135075]

39. Klintmalm G, Bergstrand A, Ringden O et al. Graft biopsy for the differentiation between nephrotoxicity and rejection in cyclosporin-A-treated renal transplant recipients. Transplant Proc. 1983; 15:493-6.

40. Starzl TE, Iwatsuki S, Malatack JJ et al. Liver and kidney transplantation in children receiving cyclosporin A and steroids. J Pediatr. 1982; 100:681-6. [IDIS 149922] [PubMed 6802949]

41. Conley SB, Brewer ED, Flechner SM et al. Renal transplantation using cyclosporine in pediatric patients 3 to 17 years old. Transplant Proc. 1983; 15(Suppl 1):2528-30.

42. Thiru S, Calne RY, Nagington J. Lymphoma in renal allograft patients treated with cyclosporin-A as one of the immunosuppressive agents. Transplant Proc. 1981; 13:359-64. [PubMed 7022852]

43. Starzl TE, Nalesnik MA, Porter KA et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet. 1984; 1:583-7. [IDIS 183262] [PubMed 6142304]

44. Nickell SP, Scheibel LW, Cole GA. Inhibition by cyclosporin A of rodent malaria in vivo and human malaria in vitro. Infect Immun. 1982; 37:1093-100. [PubMed 6752020]

45. Stiller C, Canadian Transplant Study Group. The requirements for maintenance steroids in cyclosporine-treated renal transplant recipients. Transplant Proc. 1983; 15(Suppl 1):2490-4.

46. Robinson WT, Schran HF, Barry EP. Methods to measure cyclosporine levels—high pressure liquid chromatography, radioimmunoassay, and correlation. Transplant Proc. 1983; 15(Suppl 1):2403-8.

47. Follath F, Wenk M, Vozeh S et al. Intravenous cyclosporine kinetics in renal failure. Clin Pharmacol Ther. 1983; 34:638-43. [IDIS 178355] [PubMed 6627824]

48. Stiller CR, Dupré J, Gent M et al. Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset. Science. 1984; 223:1362-7. [IDIS 182686] [PubMed 6367043]

49. Kahan BD, Wideman CA, Flechner S et al. Anaphylactic reaction to intravenous cyclosporin. Lancet. 1984; 1:52. [IDIS 180331] [PubMed 6140379]

50. Malatack JJ, Zitelli BJ, Gartner JC et al. Pediatric liver transplantation under therapy with cyclosporin-A and steroids. Transplant Proc. 1983; 15:1292-6. [PubMed 21151785]

51. Lorenz W, Schmal A, Schult H et al. Histamine release and hypotensive reactions in dogs by solubilizing agents and fatty acids: analysis of various components in Cremophor EL and development of a compound with reduced toxicity. Agents Actions. 1982; 12:64-80. [PubMed 6177219]

52. Schmutzler W, Raemsch KD, Van Wersch J et al. Allergic and pseudo-allergic reactions to micelle-forming agents: developing laboratory models to determine undesired drug effects. Allergologie. 1982; 5:208-15.

53. Moneret-Vautrin DA, Laxenaire MC, Viry-Babel F. Anaphylaxis caused by anti-Cremophor EL IgG STS antibodies in a case of reaction to Althesin. Br J Anaesth. 1983; 55:469-71. [IDIS 170561] [PubMed 6849729]

54. Dye D, Watkins J. Suspected anaphylactic reaction to Cremophor EL. Br Med J. 1980; 280:1353. [PubMed 7388538]

55. Rolles K, Calne RY. Two cases of benign lumps after treatment with cyclosporin A. Lancet. 1980; 2:795. [IDIS 125270] [PubMed 6107466]

56. Clarke RSJ. Adverse effects of intravenously administered drugs used in anaesthetic practice. Drugs. 1981; 22:26-41. [IDIS 164821] [PubMed 7021121]

57. Gramstad L, Stovner J. Plasma viscosity and Cremophor-containing anesthetics. Br J Anaesth. 1979; 51:1175-9. [PubMed 526386]

58. Hüttel MS, Schou OA, Stoffersen E. Complement-mediated reactions to diazepam with Cremophor as solvent (Stesolid MR). Br J Anaesth. 1980; 52:77-9. [IDIS 117113] [PubMed 7378233]

59. Lawler PGP, McHutchon A, Bamber PA. Potential hazards of prolonged steroid anaesthesia. Lancet. 1983; 1:1270-1. [IDIS 171417] [PubMed 6134054]

60. Forrest ARW, Watrasiewicz K, Moore CJ. Long term Althesin infusion and hyperlipidemia. Br Med J. 1977; 2:1357-8. [PubMed 589210]

61. Niell HB. Miconazole carrier solution, hyperlipidemia, and hematologic problems. N Engl J Med. 1977; 296:1479. [PubMed 865521]

62. Bagnarello AG, Lewis LA, McHenry MC et al. Unusual serum lipoprotein abnormality induced by the vehicle of miconazole. N Engl J Med. 77; 296:497-9.

63. Janssen Pharmaceutica. Monistat i.v. prescribing information. In: Huff BB, ed. Physicians’ desk reference. 38th ed. Oradell, NJ: Medical Economics Company Inc.; 1984:1025-6.

64. Watkins J, Clark A, Appleyard TN et al. Immune-mediated reactions to Althesin (alphaxalone). Br J Anaesth. 1976; 48:881-6. [PubMed 786347]

65. Food and Drug Administration. Antibiotic drugs; cyclosporine. [Docket No. 84N-0105.] Fed Regist. 1984; 49:22631-4.

66. Reviewers’ comments (personal observations); 1984 May.

67. Burckart G. Comparison of plasma and serum cyclosporine concentrations. (unpublished observations; 1984 Jun)

68. Starzl TE, Weil R III, Iwatsuki S et al. The use of cyclosporin A and prednisone in cadaver kidney transplantation. Surg Gynecol Obstet. 1980; 151:17-26. [IDIS 116659] [PubMed 6992310]

69. Starzl TE, Hakala TR, Rosenthal JT et al. Variable convalescence and therapy after cadaveric renal transplantation under cyclosporin A and steroids. Surg Gynecol Obstet. 1982; 154:819-25. [IDIS 151825] [PubMed 7043758]

70. Oryshkevich B (Sandoz, Inc, East Hanover, NJ): Personal communication; 1984 Jun.

71. Tuman W (BASF Wyandotte Corporation, Wyandotte, MI): Personal communication; 1984 Jun 12.

72. Timer E (USP, Rockville, MD): Personal communication; 1984 Jun 13.

73. Wallwork J, McGregor CGA, Wells FC et al. Cyclosporin and intravenous sulphadimidine and trimethoprim therapy. Lancet. 1983; 1:366-7. [IDIS 166076] [PubMed 6130373]

74. Joss DV, Barrett AJ, Kendra JR et al. Hypertension and convulsions in children receiving cyclosporin A. Lancet. 1982; 1:906. [IDIS 148864] [PubMed 6122119]

75. Lewis GJ, Lamont CAR, Lee HA et al. Successful pregnancy in a renal transplant recipient taking cyclosporin A. BMJ. 1983; 286:603. [IDIS 167235] [PubMed 6402165]

76. Bennett WM, Pulliam JP. Cyclosporine nephrotoxicity. Ann Intern Med. 1983; 99:851-4. [IDIS 179204] [PubMed 6360003]

77. Ost L. Effects of cyclosporin on prednisolone metabolism. Lancet. 1984; 1:451. [IDIS 182172] [PubMed 6142174]

78. Klintmalm G, Sawe J. High dose methylprednisolone increases plasma cyclosporin levels in renal transplant recipients. Lancet. 1984; 1:731. [IDIS 183361] [PubMed 6143058]

79. Gosselin RE, Hodge HC, Smith RP et al. Clinical toxicology of commercial products. Acute poisoning. 5th ed. Baltimore: The Williams & Wilkins Co; 1984:I-10.

80. Niederberger W, Lemaire M, Maurer G et al. Distribution and binding of cyclosporine in blood and tissues. In: Kahan BD, ed. Cyclosporine: biological activity and clinical applications. Orlando, FL: Grune & Stratton, Inc; 1984:203-5.

81. Stiller CR. Update for the Canadian Multicentre Trial of cyclosporine in renal allografts. N Engl J Med. 1984; 310:1464-5. [PubMed 6371537]

82. Schran HF. (Sandoz, Inc, East Hanover, NJ): Personal communication; 1984 Jul 2.

83. Schran HF, Abisch E. Monitoring of cyclosporine: a status report. Ther Drug Monit. (in press)

84. Robinson CA, Jr, Ketchum CH. Monitoring of cyclosporin A: is it possible? Ther Drug Monit. 1983; 5:371-2. Letter.

85. Ferguson RM, Fidelus-Gort R. The immunosuppressive action of cyclosporine in man. In: Kahan BD, ed. Cyclosporine: biological activity and clinical applications. Orlando, FL: Grune & Stratton, Inc; 1984:134-40.

86. Bia MJ, Flye W. Lymphoma and cyclosporin. Lancet. 1984; 1:1408. [IDIS 186827] [PubMed 6145856]

87. Varghese Z, Chan MK, Steele LV et al. How to measure cyclosporin. Lancet. 1984; 1:1407-8. [IDIS 186826] [PubMed 6145855]

88. Petersen KC, Silberman H, Berne TV. Hyperkalaemia after cyclosporin therapy. Lancet. 1984; 1:1470. [IDIS 187191] [PubMed 6145908]

89. Cho SI, Bradley JW, Monaco AP et al. Comparison of kidney transplant survival between patients treated with cyclosporine and those treated with azathioprine and antithymocyte globulin. Am J Surg. 1984; 147:518-23. [IDIS 184019] [PubMed 6370008]

90. Reviewers’ comments on Lymphocyte Immune Globulin, Antithymocyte Globulin (Equine) 92:00 (personal observations); 1985 Mar.

91. Halloran PF, Lien J, Aprile M et al. Preliminary results of a randomized comparison of cyclosporine and Minnesota antilymphoblast globulin. Transplant Proc. 1982; 14:627-30. [PubMed 6301117]

92. Najarian JS, Fryd DS, Strand M et al. A single institution, randomized, prospective trial of cyclosporine versus azathioprine-antilymphocyte globulin for immunosuppression in renal allograft recipients. Ann Surg. 1985; 201:142-57. [IDIS 196130] [PubMed 3882063]

93. Hall BM, Tiller DJ, Horvath JS et al. Treatment of renal transplantation rejection: cyclosporin A versus conventional treatment with azathioprine, prednisone and antithymocyte immunoglobulin in primary cadaveric renal transplantation. Med J Aust. 1985; 142:179-85. [IDIS 201106] [PubMed 3881654]

94. Ptachcinski RJ, Logue LW, Burckart GJ et al. Stability and availability of cyclosporine in 5% dextrose injection or 0.9% sodium chloride injection. Am J Hosp Pharm. 1986; 43:94-7. [PubMed 3953588]

95. Venkataramanan R, Burckart GJ, Ptachcinski RJ et al. Leaching of diethylhexyl phthalate from polyvinyl chloride bags into intravenous cyclosporine solution. Am J Hosp Pharm. 1986; 43:2800-2. [PubMed 3799618]

96. Canadian Multicentre Transplant Study Group. A randomized clinical trial of cyclosporine in cadaveric renal transplantation: analysis at three years. N Engl J Med. 1986; 314:1219-25. [IDIS 214836] [PubMed 2871486]

97. Deeg HJ, Storb R, Thomas ED et al. Cyclosporine as prophylaxis for graft-versus-host disease: a randomized study in patients undergoing marrow transplantation for acute nonlymphoblastic leukemia. Blood. 1985; 65:1325-34. [IDIS 201360] [PubMed 3888312]

98. Storb R, Deeg HJ, Thomas ED et al. Marrow transplantation for chronic myelocytic leukemia: a controlled trial of cyclosporine versus methotrexate for prophylaxis of graft-versus-host disease. Blood. 1985; 66:698-702. [IDIS 206064] [PubMed 2862933]

99. Irle C, Deeg HJ, Buckner CD et al. Marrow transplantation for leukemia following fractionated total body irradiation: a comparative trial of methotrexate and cyclosporine. Leuk Res. 1985; 9:1255-61. [PubMed 3906282]

100. Storb R, Deeg HJ, Whitehead J et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med. 1986; 314:729-25. [IDIS 212037] [PubMed 3513012]

101. Tutschka PJ, Hess AD, Beschorner WE et al. Cyclosporine in clinical marrow transplantation: the Baltimore experience. Transplant Proc. 1983; 15:2613-6. [PubMed 6364508]

102. Kennedy MS, Deeg HJ, Storb R et al. Treatment of acute graft-vs-host disease after allogeneic marrow transplantation: randomized study comparing corticosteroids and cyclosporine. Am J Med. 1985; 78:978-83. [IDIS 201197] [PubMed 3893112]

103. Neudorf S, Filipovich A, Ramsay N et al. Prevention and treatment of acute graft-versus-host disease. Semin Hematol. 1984; 21:91-100. [PubMed 6377502]

104. Velu T, Debusscher L, Stryckmans PA. Cyclosporin-associated fatal convulsions. Lancet. 1985; 1:219. [IDIS 195690] [PubMed 2857288]

105. Beaman M, Parvin S, Veitch PS et al. Convulsions associated with cyclosporin A in renal transplant recipients. BMJ. 1985; 290:139-40. [IDIS 195299] [PubMed 3917716]

106. Thompson CR, June CH, Sullivan KM et al. Association between cyclosporin neurotoxicity and hypomagnesaemia. Lancet. 1984; 2:1116-20. [IDIS 192622] [PubMed 6150182]

107. Sandoz Pharmaceuticals. Sandimmune (cyclosporine) practical guide. East Hanover, NJ; 1985 Sep. SDI-103.

108. Hanto DW, Gajl-Peczalska KJ, Frizzera G et al. Epstein-Barr virus (EBV) induced polyclonal and monoclonal B-cell lymphoproliferative diseases occurring after renal transplantation: clinical, pathologic, and virologic findings and implications for therapy. Ann Surg. 1983; 198:356-69. [PubMed 6311121]

109. Shepard JH, Canafax DM, Simmons RL et al. Cyclosporine-ketoconazole: a potentially dangerous drug-drug interaction. Clin Pharm. 1986; 5:468. [IDIS 216399] [PubMed 3720214]

110. Daneshmend TK. Ketoconazole-cyclosporin interaction. Lancet. 1982; 2:1342-3. [IDIS 161858] [PubMed 6128627]

111. Anon. Ketoconazole (Nizoral) interactions. Drug Interact Newsl. 1986; 6(10):U19-20.

112. Langhoff E, Madsen S. Rapid metabolism of cyclosporin and prednisone in kidney transplant patient receiving tuberculostatic treatment. Lancet. 1983; 2:1031. [IDIS 177764] [PubMed 6138578]

113. Daniels NJ, Dover JS, Schachter RK. Interaction between cyclosporin and rifampicin. Lancet. 1984; 2:639. [IDIS 190026] [PubMed 6147671]

114. Allen RDM, Hunnisett AG, Morris PJ. Cyclosporin and rifampicin in renal transplantation. Lancet. 1985; 1:980. [IDIS 199227] [PubMed 2859432]

115. Coward RA, Raftery AT, Brown CB. Cyclosporin and antituberculous therapy. Lancet. 1985; 1:1342-3.

116. Howard P, Bixler TJ, Gill B. Cyclosporine-rifampin drug interaction. Drug Intell Clin Pharm. 1985; 19:763-4. [IDIS 205311] [PubMed 4053986]

117. Keown PA, Stiller CR, Laupacis AL et al. The effects and side effects of cyclosporine: relationship to drug pharmacokinetics. Transplant Proc. 1982; 14:659-61. [PubMed 6762722]

118. Keown PA, Laupacis A, Carruthers G et al. Interaction between phenytoin and cyclosporine following organ transplantation. Transplantation. 1984; 38:304-6. [PubMed 6474556]

119. Freeman DJ, Laupacis A, Keown PA et al. Evaluation of cyclosporin-phenytoin interaction with observations on cyclosporin metabolites. Br J Clin Pharmacol. 1984; 18:887-93. [IDIS 196002] [PubMed 6529529]

120. Ptachcinski RJ, Carpenter BJ, Burckart GJ et al. Effect of erythromycin on cyclosporine levels. N Engl J Med. 1985; 313:1416-7. [IDIS 206815] [PubMed 4058537]

121. Kohan DE. Possible interaction between cyclosporine and erythromycin. N Engl J Med. 1986; 314:448. [IDIS 210452] [PubMed 3511381]

122. Martel R, Heinrichs D, Stiller CR et al. The effects of erythromycin in patients treated with cyclosporine. Ann Intern Med. 1986; 104:660-1. [IDIS 215750] [PubMed 3963664]

123. Godin JRP, Sketris IS, Belitsky P. Erythromycin–cyclosporine interaction. Drug Intell Clin Pharm. 1986; 20:504-5. [IDIS 216463] [PubMed 3522164]

124. Freeman DJ, Martell R, Carruthers SG et al. The effect of erythromycin on the pharmacokinetics of cyclosporine. Clin Pharmacol Ther. 1986; 39:193.

125. Anon. Erythromycin interactions. Drug Interact Newsl. 1986; 6:U11-2.

126. Pochet JM, Pirson Y. Cyclosporin-diltiazem interaction. Lancet. 1986; 1:979. [IDIS 215686] [PubMed 2871278]

127. Grino JM, Sabate I, Castelao AM et al. Influence of diltiazem on cyclosporin clearance. Lancet. 1986; 1:1387. [IDIS 217289] [PubMed 2872500]

128. Moody H, Matz L, Hurst P. Vascular lesions as manifestations of cyclosporin nephrotoxicity. Lancet. 1986; 1:1221-2. [IDIS 216496] [PubMed 2871465]

129. Cohen DJ, Loertscher R, Rubin MF et al. Cyclosporine: a new immunosuppressive agent for organ transplantation. Ann Intern Med. 1984; 101:667-82. [IDIS 191775] [PubMed 6385799]

130. Durrant S, Chipping PM, Palmer S et al. Cyclosporin A, methylprednisolone, and convulsions. Lancet. 1982; 1:906.

131. Boogaerts MA, Zachee P, Verwilghen RL. Cyclosporin, methylprednisolone, and convulsions. Lancet. 1982; 2:1216-7. [IDIS 161091] [PubMed 6128517]

132. Scott JP, Higenbottam TW. Adverse reactions and interactions of cyclosporin. Med Toxicol Adverse Drug Exp. 1988; 3:107-27. [IDIS 240969] [PubMed 3287088]

133. Samuel KSS, Najarian JS, Nevins TE et al. Low-dose cyclosporine therapy combined with standard immunosuppression in pediatric renal transplantation. J Pediatr. 1987; 111(6 Part 2):1017-21. [IDIS 237551] [PubMed 3316573]

134. Lin HY, Rocher LL, McQuillan MA et al. Cyclosporine-induced hyperuricemia and gout. N Engl J Med. 1989; 321:287-92. [IDIS 257647] [PubMed 2664517]

135. Ballantyne CM, Podet EJ, Patsch WP et al. Effects of cyclosporine therapy on plasma lipoprotein levels. JAMA. 1989; 262:53-6. [IDIS 256273] [PubMed 2733125]

136. Barton CH, Vaziri ND, Martin DC et al. Hypomagnesemia and renal magnesium wasting in renal transplant recipients receiving cyclosporine. Am J Med. 1987; 83:693-9. [IDIS 235291] [PubMed 3314493]

137. Pickrell MD, Sawers R, Michael J. Pregnancy after renal transplantation: severe intrauterine growth retardation during treatment with cyclosporin A. BMJ. 1988; 296:825. [IDIS 239817] [PubMed 3130929]

138. de Groen PC, Aksamit AJ, Rakela J et al. Central nervous system toxicity after liver transplantation: the role of cyclosporine and cholesterol. N Engl J Med. 1987; 317:861-6. [IDIS 233870] [PubMed 3306386]

139. Klintmalm G, Althoff P, Appleby G et al. Renal function in a newborn baby delivered of a renal transplant patient taking cyclosporine. Transplantation. 1984; 38:198-9. [PubMed 6380049]

140. Stahl RAK, Kanz L, Maier B et al. Hyperchloremic metabolic acidosis with high serum potassium in renal transplant recipients: a cyclosporine A associated side effect. Clin Nephrol. 1986; 25:245-8. [PubMed 3521998]

141. Hamilton DV, Evans DB, Thiru S. Toxicity of cyclosporin A in organ grafting. In: Cyclosporin A: proceedings of an International Conference on Cyclosporin. New York: Elsevier Biomedical Press; 1981:393-410.

142. Hamilton DV, Evans DB, Henderson RG et al. “Nephrotoxicity” and metabolic acidosis in transplant patients on cyclosporin A. Proc Eur Dial Transplant Assoc. 1981; 18:400-7. [PubMed 7036160]

143. Adu D, Michael J, Turney J et al. Hyperkalemia in cyclosporin-treated renal allograft recipients. Lancet. 1983; 2:370-2. [IDIS 174759] [PubMed 6135874]

144. Thompson CB, June CH, Sullivan KM et al. Association between cyclosporin neurotoxicity and hypomagnesaemia. Lancet. 1984; 2:1116-20. [IDIS 192622] [PubMed 6150182]

145. June CH, Thompson CB, Kennedy MS et al. Profound hypomagnesemia and renal magnesium wasting associated with the use of cyclosporine for marrow transplantation. Transplantation. 1985; 39:620-4. [PubMed 3890292]

146. Cohen SL, Boner G, Rosenfeld JB et al. The mechanism of hyperuricaemia in cyclosporine-treated renal transplant recipients. Transplant Proc. 1987; 19:1829-30. [PubMed 3079042]

147. Chapman JR, Griffiths D, Harding NGL et al. Reversibility of cyclosporin nephrotoxicity after three months’ treatment. Lancet. 1985; 1:128-30. [IDIS 195824] [PubMed 2857212]

148. Tiller DJ, Hall BM, Horvarth JS et al. Gout and hyperuricaemia in patients on cyclosporin and diuretics. Lancet. 1985; 1:453. [IDIS 196868] [PubMed 2857822]

149. Leunissen KML, Bosman F, van Hooff JP. Cyclosporin, uric acid, and the kidney. Lancet. 1985; 1:702.

150. Loughran TP Jr, Deeg HJ, Dahlberg S et al. Incidence of hypertension after marrow transplantation among 112 patients randomized to either cyclosporine or methotrexate as graft-versus-host disease prophylaxis. Br J Haematol. 1985; 59:547-53. [PubMed 3882141]

151. Weidle PJ, Vlasses PH. Systemic hypertension associated with cyclosporine: a review. Drug Intell Clin Pharm. 1988; 22:443-51. [IDIS 241792] [PubMed 3293956]

152. Thompson ME, Shapiro AP, Johnsen AM et al. The contrasting effects of cyclosporin-A and azathioprine on arterial blood pressure and renal function following cardiac transplantation. Int J Cardiol. 1986; 11:219-29. [PubMed 3519476]

153. Rubin AM, Kang H. Cerebral blindness and encephalopathy with cyclosporin A toxicity. Neurology. 1987; 37:1072-6. [IDIS 230139] [PubMed 3587633]

154. Adams DH, Ponsford S, Gunson B et al. Neurological complications following liver transplantation. Lancet. 1987; 1:949-51. [IDIS 229230] [PubMed 2882342]

155. Berden JHM, Hoitsma AJ, Merx JL et al. Severe central nervous system toxicity associated with cyclosporin. Lancet. 1985; 1:219-20. [IDIS 195691] [PubMed 2857289]

156. Oyer PE, Stinson EB, Jamieson SW et al. Cyclosporine in cardiac transplantation: a 2½ year follow-up. Transplant Proc. 1983; 15:246-52.

157. Bennett WM, Porter GA. Cyclosporine-associated hypertension. Am J Med. 1988; 85:131-3. [IDIS 245301] [PubMed 3400689]

158. Curtis JJ, Luke RG, Jones P. Hypertension in cyclosporine-treated renal transplant recipients is sodium dependent. Am J Med. 1988; 85:134-8. [IDIS 245302] [PubMed 3041828]

159. Sennesael JJ, Dupont AG, Verbeelen DL et al. Hypertension and cyclosporine. Ann Intern Med. 1986; 104:729. [IDIS 215762] [PubMed 3754408]

160. Mordy DL, Oyer PE, Jamieson SW et al. Cyclosporine in heart and heart-lung transplantation. Can J Surg. 1985; 28:274-82. [PubMed 3922606]

161. Beveridge T. Cyclosporin-A: an evaluation of clinical results. Transplant Proc. 1983; 15:433-7.

162. European Multicentre Trial Group. Cyclosporin in cadaveric renal transplantation: one-year follow-up of a multicentre trial. Lancet. 1983; 2:986-9. [IDIS 177744] [PubMed 6138592]

163. Atkinson K, Biggs J, Darveniza P et al. Cyclosporin-associated central nervous system toxicity after allogenic bone marrow transplantation. Transplantation. 1984; 38:34-7. [PubMed 6377609]

164. Joss DV, Barrett AJ, Kendra JR et al. Hypertension and convulsions in children receiving cyclosporin A. Lancet. 1982; 1:906. [IDIS 148864] [PubMed 6122119]

165. Beaman M, Parvin S, Veitch PS et al. Convulsions associated with cyclosporin A in renal transplant recipients. BMJ. 1985; 290:139-40. [IDIS 195299] [PubMed 3917716]

166. Laupacis A. Complications of cyclosporin therapy—a comparison to azathioprine. Transplant Proc. 1983; 15:2748-53.

167. Foley RJ, Van Buren CT, Hamner R et al. Cyclosporin-associated hyperkalemia. Transplant Proc. 1983; 15:2726-9.

168. Geigy. Voltaren prescribing information. Ardsley, NY; 1988 Jul.

169. Deray G, Le Hoang P, Aupetit B et al. Enhancement of cyclosporine A nephrotoxicity by diclofenac. Clin Nephrol. 1987; 27:213-4. [PubMed 2953512]

170. Sandoz Pharmaceuticals. Sandimmune (cyclosporine) soft gelatin capsules oral solution, and concentrate for injection prescribing information. East Hanover, NJ; 1991 Jul 15.

171. Sandoz Pharmaceuticals. Sandimmune (cyclosporine) soft gelatin capsules pharmacy fact sheet. East Hanover, NJ; 1990 Mar.

172. Zehnder C, Beveridge T, Nüesch E et al. Cyclosporine A capsules: bioavailability and clinical acceptance study in renal transplant patients. Transplant Proc. 1988; 20(Suppl 2):641-3. [PubMed 3284114]

173. Bleck JS, Nashan B, Christians U et al. Single dose pharmacokinetics of ciclosporin and its main metabolites after oral ciclosporin as oily solution or capsule. Arzneimittelforschung. 1990; 40:62-4. [PubMed 2340002]

174. Upjohn Co. Depo-Medrol (methylprednisolone acetate) sterile aqueous suspension and sterile suspension prescribing information. In: Barnhart ER, publisher. Physicians’ desk reference. 45th ed. Oradell, NJ: Medical Economics Company Inc.; 1991(Suppl A):A72.

175. Upjohn Co. Solu-Medrol (methylprednisolone sodium succinate) sterile powder and for injection prescribing information. In: Barnhart ER, publisher. Physicians’ desk reference. 45th ed. Oradell, NJ: Medical Economics Company Inc.; 1991(Suppl A):A73.

176. Upjohn Co. Medrol (methylprednisolone) tablets prescribing information. In: Barnhart ER, publisher. Physicians’ desk reference. 45th ed. Oradell, NJ: Medical Economics Company Inc.; 1991(Suppl A):A73.

177. Lichtiger S, Present DH, Kornbluth A et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994; 330:1841-5. [IDIS 331237] [PubMed 8196726]

178. Sartor RB. Cyclosporine therapy for inflammatory bowel disease. N Engl J Med. 1994; 330:1897-8. [IDIS 331243] [PubMed 8196735]

179. Treem WR, Hyams JS. Cyclosporine therapy for gastrointestinal disease. J Pediatr Gastroenterol Nutr. 1994; 18:270-8. [IDIS 329123] [PubMed 8057207]

180. Allgayer H, Seitz KH, Gugler R. Can cyclosporin prevent proctocolectomy in severe steroid-refractory ulcerative colitis? Lessons from a case report. Dig Dis Sci. 1993; 38:380-2. [IDIS 309704] [PubMed 8425455]

181. Brynskov J. Cyclosporin for inflammatory bowel disease: mechanisms and possible actions. Scand J Gastroenterol. 1993; 28:849-57. [IDIS 321539] [PubMed 8266013]

182. Sandborn WJ, Tremaine WJ. Cyclosporine treatment of inflammatory bowel disease. Mayo Clin Proc. 1992; 67:981-90. [IDIS 303304] [PubMed 1434859]

183. Sandborn WJ, Goldman DH, Lawson GM et al. Measurement of colonic tissue cyclosporine concentration in children with severe ulcerative colitis. J Pediatr Gastroenterol Nutr. 1992; 15:125-9. [IDIS 300315] [PubMed 1357126]

184. Treem WR, Davis PM, Hyams JS. Cyclosporine treatment of severe ulcerative colitis in children. J Pediatr. 1991; 119:994-7. [IDIS 293152] [PubMed 1960626]

185. Lichtiger S, Present DH. Preliminary report: cyclosporin in treatment of severe active ulcerative colitis. Lancet. 1990; 336:16-9. [IDIS 268294] [PubMed 1973211]

186. Porro GB, Petrillo M, Ardizzone S. Cyclosporin treatment for severe active ulcerative colitis. Lancet. 1990; 336:439. [IDIS 269913] [PubMed 1974964]

187. Stange EF, Fleig WE, Rehklau E et al. Cyclosporin A treatment in inflammatory bowel disease. Dig Dis Sci. 1989; 34:1387-92. [IDIS 303802] [PubMed 2766906]

188. Van Thiel DH. Cyclosporine and inflammatory bowel disease. Dig Dis Sci. 1989; 34:1817-9. [IDIS 305065] [PubMed 2598750]

189. Hyams JS, Treem WR. Cyclosporine treatment of fulminant colitis. J Pediatr Gastroenterol Nutr. 1989; 9:383-7. [IDIS 260534] [PubMed 2614627]

190. Gupta S, Keshavarzian A, Hodgson HJF. Cyclosporin in ulcerative colitis. Lancet. 1984; 2:1277-8. [IDIS 193285] [PubMed 6150306]

191. Sandborn WJ, Wiesner RH, Tremaine WJ et al. Ulcerative colitis disease activity following treatment of associated primary sclerosing cholangitis with cyclosporin. Gut. 1993; 34:242-6. [IDIS 309914] [PubMed 8432481]

192. Ferzoco SJ, Becker JM. Does aggressive medical therapy for acute ulcerative colitis result in a higher incidence of staged colectomy? Arch Surg. 1994; 129:420-4. (IDIS 327639)

193. Winter TA, Dalton HR, Merrett MN et al. Cyclosporin A retention enemas in refractory distal ulcerative colitis and “pouchitis.” Scand J Gastroenterol. 1993; 28:701-4. (IDIS 319335)

194. Brynskov J, Freund L, Thomsen OO et al. Treatment of refractory ulcerative colitis with cyclosporin enemas. Lancet. 1989; 1:721-2. [IDIS 254029] [PubMed 2564527]

195. Ranzi T, Campanini MC, Velio P et al. Treatment of chronic proctosigmoiditis with cyclosporin enemas. Lancet. 1989; 2:97. [IDIS 257173] [PubMed 2567886]

196. Sandborn WJ, Tremaine WJ, Schroeder KW et al. A placebo-controlled trial of cyclosporine enemas for mildly to moderately active left-sided ulcerative colitis. Gastroenterology. 1994; 106:1429-35. [IDIS 330413] [PubMed 8194687]

197. Sandborn WJ, Tremaine WJ, Schroeder KW et al. Cyclosporine enemas for treatment-resistant, mildly to moderately active, left-sided ulcerative colitis. Am J Gastroenterol. 1993; 88:640-6. [IDIS 313817] [PubMed 8480724]

198. Present DH. Cyclosporine and other immunosuppressive agents: current and future role in the treatment of inflammatory bowel disease. Am J Gastroenterol. 1993; 88:627-9. [IDIS 313815] [PubMed 8480721]

199. Brynskov J, Freund L, Rasmussen SN et al. A placebo-controlled, double-blind, randomized trial of cyclosporine therapy in active chronic Crohn’s disease. N Engl J Med. 1989; 321:845-50. [IDIS 259043] [PubMed 2671739]

200. Sachar DB. Cyclosporine treatment for inflammatory bowel disease: a step backward or a leap forward? N Engl J Med. 1989; 321:894-6. Editorial.

201. Lobo AJ, Juby LD, Axon ATR. Cyclosporine in Crohn’s disease. N Engl J Med. 1990; 322:636. [IDIS 263302] [PubMed 2406605]

202. Feagan BG, Archambault A, Fedorak R et al. Cyclosporine in Crohn’s disease. N Engl J Med. 1990; 322:636-7. [IDIS 263302] [PubMed 2406605]

203. Brynskov J, Binder V, Riis P. Cyclosporine in Crohn’s disease. N Engl J Med. 1990; 322:637. [IDIS 263303] [PubMed 2304516]

204. Sachar DB. Cyclosporine in Crohn’s disease. N Engl J Med. 1990; 322:637. [IDIS 263303] [PubMed 2304516]

205. Ardizzone S, Fasoli R, Sangaletti O et al. The treatment of chronically active Crohn’s disease with cyclosporin A: a preliminary report. Curr Ther Res. 1990; 48:1-4.

206. Ranzi T, Campanini MC, Di Palo FQ et al. Cyclosporin A in Crohn’s disease. Curr Ther Res. 1989; 45:245-52.

207. Löfberg R, Angelin B, Einarsson K et al. Unsatisfactory effect of cyclosporin A treatment in Crohn’s disease: a report of five cases. J Intern Med. 1989; 226:157-61. [IDIS 300541] [PubMed 2677208]

208. Allam BF, Tillman JE, Thomson TJ et al. Effective intravenous cyclosporin therapy in a patient with severe Crohn’s disease on parenteral nutrition. Gut. 1987; 28:1166-9. [IDIS 243141] [PubMed 3119435]

209. Allison MC, Pounder RE. Cyclosporin for Crohn’s disease. Lancet. 1984; 1:902-3. [IDIS 184604] [PubMed 6143202]

210. Brynskov J, Freund L, Rasmussen SN et al. Final report on a placebo-controlled, double-blind, randomized, multicentre trial of cyclosporin treatment in active chronic Crohn’s disease. Scand J Gastroenterol. 1991; 26:689-95. [IDIS 285203] [PubMed 1896809]

211. Feagan BG, McDonald JWD, Rochon J et al. Low-dose cyclosporine for the treatment of Crohn’s disease. N Engl J Med. 1994; 330:1846-51. [IDIS 331238] [PubMed 8196727]

212. Present DH, Lichtiger S. Efficacy of cyclosporine in treatment of fistula of Crohn’s disease. Dig Dis Sci. 1994; 39:374-80. [IDIS 325113] [PubMed 8313821]

213. Hanauer SB, Smith MB. Rapid closure of Crohn’s disease fistulas with continuous intravenous cyclosporin A. Am J Gastroenterol. 1993; 88:646-9. [IDIS 313818] [PubMed 8480725]

214. Sanderson IR, Phillips AD, Spencer J et al. Response to autoimmune enteropathy to cyclosporin A therapy. Gut. 1991; 32:1421-5. [IDIS 291456] [PubMed 1752480]

215. Seidman EG, Lacaille F, Russo P et al. Successful treatment of autoimmune enteropathy with cyclosporine. J Pediatr. 1990; 117:929-32. [IDIS 299538] [PubMed 2246696]

216. Coulthard M, Searle J, Patrick M et al. Cyclosporin-responsive enteropathy and protracted diarrhea. J Pediatr Gastroenterol Nutr. 1990; 10:257-61. [IDIS 300888] [PubMed 2303980]

217. Bernstein EF, Whitington PF. Successful treatment of atypical sprue in an infant with cyclosporine. Gastroenterology. 1988; 95:199-204. [IDIS 242662] [PubMed 3371614]

218. Longstreth GF. Successful treatment of refractory sprue with cyclosporine. Ann Intern Med. 1993; 119:1014-6. [IDIS 322035] [PubMed 8214978]

219. Lombard M, Portmann B, Neuberger J et al. Cyclosporin A treatment in primary biliary cirrhosis: results of a long-term placebo controlled trial. Gastroenterology. 1993; 104:519-26. [IDIS 308808] [PubMed 8425695]

220. Wiesner RH, Ludwig J, Lindor KD et al. A controlled trial of cyclosporine in the treatment of primary biliary cirrhosis. N Engl J Med. 322:1419-24.

221. Minuk GY, Bohme CE, Burgess E et al. Pilot study of cyclosporin A in patients with symptomatic primary biliary cirrhosis. Gastroenterology. 1988; 95:1356-63. [IDIS 250302] [PubMed 3169499]

222. Routhier G, Epstein O, Janossy G et al. Effects of cyclosporin A on suppressor and induced T lymphocytes in primary biliary cirrhosis. Lancet. 1980; 2:1223-6. [IDIS 125903] [PubMed 6108396]

223. Munoz SJ. Cyclosporine in primary biliary cirrhosis. N Engl J Med. 1990; 323:1352. [IDIS 273273] [PubMed 2215626]

224. Laburte C, Grossman R, Abi-Rached J et al. Efficacy and safety of oral cyclosporin A (CyA; Sandimmun) for long-term treatment of chronic severe plaque psoriasis. Br J Dermatol. 1994; 130:366-75. [IDIS 327074] [PubMed 8148280]

225. Ellis CN, Fradin MS, Messana JM et al. Cyclosporine for plaque-type psoriasis. N Engl J Med. 1991; 324:277-84. [IDIS 277122] [PubMed 1986287]

226. Lowe NJ. Systemic treatment of severe psoriasis: the role of cyclosporine. N Engl J Med. 1991; 324:333-4. [IDIS 277127] [PubMed 1986292]

227. Rapaport M. Cyclosporine for treatment of psoriasis. N Engl J Med. 1991; 324:1894. [IDIS 282306] [PubMed 2041556]

228. Ellis CN, Fradin MS, Brown MD et al. Cyclosporine for treatment of psoriasis. N Engl J Med. 1991; 324:1895. [PubMed 1645846]

229. Meinardi MMH, De Rie MA, Bos JD. Oral cyclosporin A in the treatment of psoriasis: an overview of studies performed in The Netherlands. Br J Dermatol. 1990; 122(Suppl 36):27-31. [IDIS 268222] [PubMed 2196081]

230. Powles AV, Baker BS, Valdimarsson H et al. Four years of experience with cyclosporin A for psoriasis. Br J Dermatol. 1990; 122(Suppl 36):13-9. [IDIS 268220] [PubMed 2369568]

231. Timonen P, Friend D, Abeywickrama K et al. Efficacy of low-dose cyclosporin A in psoriasis: results of dose-finding studies. Br J Dermatol. 1990; 122(Suppl 36):33-9. [IDIS 268223] [PubMed 2196082]

232. Fradin MS, Ellis CN, Voorhees JJ. Efficacy of cyclosporin A in psoriasis: a summary of the United States’ experience. Br J Dermatol. 1990; 122(Suppl 36):21-5. [IDIS 268221] [PubMed 2196080]

233. Griffiths CEM, Powles AV, McFadden J et al. Long-term cyclosporin for psoriasis. Br J Dermatol. 1989; 120:253-60. [IDIS 252984] [PubMed 2923798]

234. Van Joost T, Bos JD, Heule F et al. Low-dose cyclosporin A in severe psoriasis: a double-blind study. Br J Dermatol. 1988; 118:183-90. [IDIS 239542] [PubMed 3280000]

235. Wentzell JM, Baughman RD, O’Connor GT et al. Cyclosporine in the treatment of psoriasis. Arch Dermatol. 1987; 123:163-5. [IDIS 225168] [PubMed 3813586]

236. Ellis CN, Gorsulowsky DC, Hamilton TA et al. Cyclosporine improves psoriasis in a double-blind study. JAMA. 1986; 256:3110-6. [IDIS 223714] [PubMed 3023712]

237. Brookes DB. Clearance of psoriasis with low dose cyclosporin. BMJ. 1986; 293:1098-9. [IDIS 222849] [PubMed 3094789]

238. Griffiths CEM, Powles AV, Leonard JN et al. Clearance of psoriasis with low dose cyclosporin. BMJ. 1986; 293:731-2. [IDIS 221497] [PubMed 3094629]

239. Marks JM. Cyclosporin A treatment of severe psoriasis. Br J Dermatol. 1986; 115:745-6. [IDIS 224535] [PubMed 3542010]

240. Marks J. Psoriasis. BMJ. 1986; 293:509. [IDIS 220438] [PubMed 3091187]

241. Van Joost T, Huele F, Stolz E et al. Short-term use of cyclosporin A in severe psoriasis. Br J Dermatol. 1986; 114:615-20. [IDIS 216357] [PubMed 3718852]

242. van Hoofe JP, Leunissen KML, Staak W. Cyclosporin and psoriasis. Lancet. 1985; 1:335.

243. Harper JI, Keat ACS, Staughton RCD. Cyclosporin for psoriasis. Lancet. 1984; 2:981-2.

244. Mueller W, Herrmann B. Cyclosporin A for psoriasis. N Engl J Med. 1979; 301:555. [IDIS 100685] [PubMed 460314]

245. Cacoub P, Artru L, Canesi M J et al. Life-threatening psoriasis relapse on withdrawal of cyclosporin. Lancet. 1988; 2:219-20.

246. Powles AV, Baker BS, McFadden et al. Psoriasis and cyclosporin withdrawal. Lancet. 1988; 2:513. [IDIS 245753] [PubMed 2900438]

247. Burnes MK, Ellis CN, Eisen D et al. Intralesional cyclosporine for psoriasis. Arch Dermatol. 1992; 128:786-90. [IDIS 297969] [PubMed 1599264]

248. Powles AV, Baker BS, McFadden J et al. Intralesional injection of cyclosporin in psoriasis. Lancet. 1988; 1:537. [IDIS 239510] [PubMed 2893957]

249. Mizoguchi M, Kawaguchi K, Ohsuga Y et al. Cyclosporin ointment for psoriasis and atopic dermatitis. Lancet. 1992; 339:1120. [IDIS 296289] [PubMed 1349141]

250. Schulze HJ, Mahrle G, Stiegleder GK. Topical cyclosporin A in psoriasis. Br J Dermatol. 1990; 122:113-4. [IDIS 262491] [PubMed 2297498]

251. Griffiths CEM, Powles AV, Baker BS et al. Topical cyclosporin and psoriasis. Lancet. 1987; 1:806. [IDIS 228024] [PubMed 2882209]

252. Thomson AW, Sewell HF, Aldridge RD. Topical cyclosporin and immunologically- mediated skin disorders. Lancet. 1987; 1:1212. [IDIS 229744] [PubMed 2883531]

253. Petzelbauer P, Hönigsmann H, Langer K et al. Cyclosporin A in combination with photochemotherapy (PUVA) in the treatment of psoriasis. Br J Dermatol. 1990; 123:641- 7. [IDIS 275400] [PubMed 2248892]

254. Brechtel B, Wellenreuther U, Toppe E et al. Combination of etretinate with cyclosporine in the treatment of severe recalcitrant psoriasis. J Am Acad Dermatol. 1994; 30:1023-4. [IDIS 330013] [PubMed 8188867]

255. Meinardi MMH, Westerhof W, Bos JD. Generalized pustular psoriasis (von Zumbusch) responding to cyclosporin A. Br J Dermatol. 1987; 116:269-70. [IDIS 226420] [PubMed 3828221]

256. Arnold WP, Gerritsen MJP, Van de Kerkof PCM. Response of nail psoriasis to cyclosporin. Br J Dermatol. 1993; 129:750-1. [IDIS 323128] [PubMed 8286269]

257. Reitamo S, Erkko P, Remitz A et al. Cyclosporine in the treatment of palmoplantar pustulosis. Arch Dermatol. 1993; 129:1273-9. [IDIS 320688] [PubMed 8215491]

258. Baughman RD. Psoriasis and cigarettes: another nail in the coffin. Arch Dermatol. 1993; 129:1329-30. [IDIS 320691] [PubMed 8215501]

259. Reitamo S, Puska P, Lassus A. Cyclosporin in the treatment of palmo-plantar pustulosis. Br J Dermatol. 1989; 120:857. [IDIS 265530] [PubMed 2667617]

260. Wiesner RH, Ludwig J, Lindor KD et al. Cyclosporine in primary biliary cirrhosis. N Engl J Med. 1990; 323:1352.

261. Häyry P, von Willebrand E. Use of fine needle aspiration biopsy in differential diagnosis between nephrotoxicity and rejection. Contr Nephrol. 1986; 51:147-51.

262. Kim EE, Pjura G, Lowry P et al. Cyclosporin-A nephrotoxicity and acute cellular rejection in renal transplant recipients: correlation between radionuclide and histologic findings. Radiology. 1986; 159:443-6. [IDIS 215737] [PubMed 3515421]

263. Mihatsch MJ, Steiner K, Abeywickrama KH et al. Risk factors for the development of chronic cyclosporine-nephrotoxicity. Clinical Nephrology. 1988; 29:165-75. [PubMed 3284669]

264. Parvin SD, Rees Y, Veitch PS et al. Objective measurement by ultrasound to distinguish cyclosporin A toxicity from rejection. Br J Surg. 1986; 73:1009-11. [PubMed 3539254]

265. Salaman JR, Ross WB, Griffin PJA e tal. Intrarenal pressure and renal transplant survival. Clin Transplantation. 1988; 2:228-30.

266. te Strake L, Kool LJS, Paul LC et al. Magnetic resonance imaging of renal transplants: its value in the differentiation of acute rejection and cyclosporin A nephrotoxicity. Clinical Radiology. 1988; 39:220-8. [PubMed 3293883]

267. von Willebrand E, Häyry. Cyclosporin-A deposits in renal allografts. Lancet. 1983; 2:189-92. [IDIS 173742] [PubMed 6135029]

268. Winkelmann M, Bürrig KF, Koldovsky U et al. Cyclosporin A: altered renal tubular cells in urinary cytology. Lancet. 1985; 2: 667. [IDIS 205581] [PubMed 2863653]

269. Taube DH, Williams DG, Hartley B et al. Differentiation between allograft rejection and cyclosporin nephrotoxicity in renal-transplant recipients. Lancet. 1985: 2:171-4.

270. Burke JF Jr, Pirsh JD, Ramos EL et al. Long-term efficacy and safety of cyclosporine in renal-transplant recipients. N Engl J Med. 1994; 331:358-63. [IDIS 333593] [PubMed 8028616]

271. Luke RG. New issues in therapy after renal transplantation. N Engl J Med. 1994; 331:393-4. [IDIS 333595] [PubMed 8028621]

272. Singh AK. Efficacy and safety of cyclosporine in renal-transplant recipients. N Engl J Med. 1994; 331:1777. [IDIS 340274] [PubMed 7984210]

273. Bennett WM. Efficacy and safety of cyclosporine in renal-transplant recipients. N Engl J Med. 1994; 331:1777. [IDIS 340275] [PubMed 7984209]

274. Burke JF Jr, Pirsch JD, Salomon DR. Efficacy and safety of cyclosporine in renal- transplant recipients. N Engl J Med. 1994; 331:1777-8.

275. Holt DW, Marsden JT, Johnston A et al. Blood cyclosporin concentrations and renal allograft dysfunction. BMJ. 1986; 293:1057-9. [IDIS 222837] [PubMed 3094774]

276. Irschik E, Tilg H, Niederwieser D et al. Cyclosporin blood levels do correlate with clinical complications. Lancet. 1984; 2: ? Letter. [IDIS 190417] [PubMed 6147710]

277. Lindholm A, Dahlqvist R, Groth GG et al. A prospective study of cyclosporine concentration in relation to its therapeutic effect and toxicity after renal transplantation. Br J Clin Phrmacol. 1990; 30:443-52.

278. Moyer TP, Post GR, Sterioff S et al. Cyclosporine nephrotoxicity is minimized by adjusting dosage on the basis of drug concentration in blood. Mayo Clin Proc. 1988; 63:241-7. [IDIS 239665] [PubMed 3278174]

279. Lindholm A, Kahan BD. Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation. Clin Pharmacol Ther. 1993; 54:205-18. [IDIS 319213] [PubMed 8354028]

280. Schroeder TJ, Sridhar N, Pesce AJ et al. Clinical correlations of cyclosporine-specific and -nonspecific assays in stable renal transplants, acute rejection, and cyclosporine nephrotoxicity. Ther Drug Monit. 1993; 15:190-4. [IDIS 317074] [PubMed 8332997]

281. Canafax DM. Minimizing cyclosporine concentration variability to optimize transplant outcome. Clin Transplantation. 1995; 9:1-13.

282. Lindholm A. Therapeutic monitoring of cyclosporin: an update. Eur J Clin Pharmacol. 1991; 41:273-83. [IDIS 291517] [PubMed 1804639]

283. Bishop GA, Waugh J, Horvath JS et al. Diagnosis of renal allograft rejection by analysis of fine-needle aspiration biopsy specimens with immunostains and simple cytology. Lancet. 1986; 2:645-50. [PubMed 2876134]

284. Cortesini R, Stella F, Molajoni ER et al. Urinary exfoliative cytology in kidney allografts under cyclosporine therapy. Transplantation Proceedings. 1984; 16:1200-1. [PubMed 6385377]

285. Desir G, Lange R, Smith E et al. Differentiation of acute rejection from cyclosporine nephrotoxicity and acute tubular necrosis by indium-111 labelled platelet scintigraphy. Clinical Research. 1985; 33:481A.

286. Hricak H, Terrier F, Demas BE. Renal allografts: evaluation by MR imaging. Radiology. 1986; 159:435-41. [PubMed 3515420]

287. Jurewicz WA, Dykes JGA, Gunson BK et al. Indium-111-labeled platelets as a diagnostic aid in posttransplant monitoring of renal allografts in humans. Transplantation Proceedings. 1984; 16:1481-3. [PubMed 6390850]

288. Kahan BD. Clinical summation: an algorithm for the management of patients with cyclosporine-induced renal dysfunction. Transplantation Proceedings. 1985; 17(Suppl 1):303-8. [PubMed 3895669]

289. Klintmalm G, Ringdén O, Groth CG. Clinical and laboratory signs in nephrotoxicity and rejection in cyclosporine-treated renal allograft recipients. Transplantation Proceedings. 1983; 15(Suppl 1): 2815-20.

290. Matas AJ, Tellis VA, Quinn T et al. Definition, diagnosis, and management of rejection in the second to sixth months posttransplant: an overview. Trnasplantation Proceedings. 1986; 18(Suppl 1): 141-7.

291. Oh C-S, Stratta RJ, Pirsch JD et al. A simple and reliable way of differentiating acute rejection from cyclosporine nephrotoxicity in renal transplantation. Transplantation. 46:311-2.

292. Pjura GA, Kim EE, Lowry PA et al. Radionuclide differentiation of acute cellular rejection from ciclosporin nephrotoxicity. Contr Nephrol. 1987; 56:163-7.

293. Salaman JR, Griffin PJA. Fine needle intrarenal manometry in the management of renal transplant patients receiving cyclosporine. Transplantation Proceedings. 1985; 17:1275-6.

294. Sibley RK, Rynasiewicz J, Ferguson RM et al. Morphology of cyclosporine nephrotoxicity and acute rejection in patients immunosuppressed with cyclosporine and prednisone. Surgery. 1983; 94:225-34. [PubMed 6348988]

295. Sibley RK, Ferguson RM, Sutherland DER et al. Morphology of cyclosporine nephrotoxicity -prednisone immunosuppressed renal allograft recipients. Transplantation Proceedings. 1983; 15(Suppl 1):2836-41.

296. Solez K, McGraw DJ, Beschorner WE et al. Reflections on use of the renal biopsy as the “gold standard” in distinguishing transplant rejection from cyclosporine nephrotoxicity. Transplantation Proceedings. 1985; 17(Suppl 1): 123-33. [PubMed 3927535]

297. Taube D, Neild G, Hobby P et al. A comparison of the clinical, histopathologic, cytologic, and biochemical features of renal transplant rejection, cyclosporine A nephrotoxicity , and stable renal function. Transplantation Proceedings. 1985; 17(Suppl 1): 179-84. [PubMed 3895658]

298. Ubhi CS, Guillou PJ, Davison AM et al. Combination fine-needle aspiration cytology and intrarenal manometry at the onset of renal dysfunction. Br J Surg. 1987; 74:297-300. [PubMed 3555693]

299. Wagner E, Pichlmayr R, Wonigeit K et al. Differentiation between rejection and cyclosporin-A nephrotoxicity by monitoring interstitial pressure in human renal allografts. Transplantation Proceedings. 1983; 15:489-92.

300. Wijeyesinghe ECR, Hawkins T, Keavey P et al. Techmetium-99m tin colloid: its value in the diagnosis of renal transplant rejection and its potential for differentiating cyclosporin nephrotoxicity. Kidney International. 1985; 27:351.

301. Wilson RG, Shenton BK, Taylor RMR et al. Aspirate cellularity as a rapid indicator of renal allograft rejection. Br J Surgery. 1986; 73:116-7.

302. Keown PA, Stiller CR, Wallace AC. Effect of cyclosporine on the kidney. J Pediatr. 1987; 111:1029-33. [IDIS 237553] [PubMed 3316576]

303. Cyclosporine interactions. In: Tatro DS, Olin BR, Hebel SK, eds. Drug interaction facts. St. Louis: JB Lippincott Co; 1995:229a,230a,233,237,238,238a,238b,238d,240,240a,242,278a,479b.

304. Norman DJ, Illingworth DR, Munson J et al. Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin. N Engl J Med. 1988; 318:46-7. [IDIS 236485] [PubMed 3275891]

305. East C, Alivizatos PA, Grundy SM et al. Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation. N Engl J Med. 1988; 318:47-8. [IDIS 236486] [PubMed 3275892]

306. Tobert JA. Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation. N Engl J Med. 1988; 318:48. [IDIS 236487] [PubMed 3257291]

307. Corpier CL, Jones PH, Suki WN et al. Rhabdomyolysis and renal injury with lovastatin use. JAMA. 1988; 260:239-41. [IDIS 243599] [PubMed 3290520]

308. Cyclosporine interactions. In: Hansten PD, Horn JR. Drug interactions and updates. Vancouver, WA: Applied Therapeutics, Inc; 1993:201,244-5,335-6,391,393-4,411,463-4,499,541-2,569-71,575,578,854.

309. Schofield OMV, Camp RDR, Levene GM. Cyclosporin A in psoriasis: interaction with carbamazepine. Br J Dermatol. 1990; 122: 425. [IDIS 264656] [PubMed 2322504]

310. Dorian P, Strauss M, Cardella C et al. Digoxin-cyclosporine interaction: severe digitalis toxicity after cyclosporine treatment. Clin Invest Med. 1988; 11:108-12. [PubMed 3396255]

311. Robieux I, Dorian P, Klein J et al. The effects of cardiac transplantation and cyclosporine therapy on digoxin pharmacokinetics. J Clin Pharmacol. 1992; 32:338-43. [IDIS 295756] [PubMed 1569236]

312. Sands M, Brown RB. Interactions of cyclosporine with antimicrobial agents. Rev Infect Dis. 1989; 11:691-7. [IDIS 307740] [PubMed 2682943]

313. Morgenstern GR, Powles R, Robinson B et al. Cyclosporin interaction with ketoconazole and melphalan. Lancet. 1982; 2:1342. [IDIS 161857] [PubMed 6128626]

314. Zylber-Katz E, Rubinger D, Berlatzky Y. Cyclosporine interactions with metronidazole and cimtidine. Drug Intell Clin Pharm. 1988; 22:504-5. [IDIS 241804] [PubMed 3293960]

315. Sugar AM, Saunders C, Idelson BA et al. Interaction of fluconazole and cyclosporine. Ann Intern Med. 1989; 110:844. [IDIS 254579] [PubMed 2540690]

316. Collignon P, Hurley B, Mitchell D. Interaction of fluconazole with cyclosporin. Lancet. 1989; 1:1262. [IDIS 255579] [PubMed 2566800]

317. Ehninger G, Jaschonek K, Schuler U et al. Interaction of fluconazole with cyclosporin. Lancet. 1989; 2:104-5. [IDIS 257180] [PubMed 2567846]

318. Collignon P, Hurley B. Interaction between fluconazole and cyclosporin. Lancet. 1989; 2:867-8. [IDIS 259605] [PubMed 2571795]

319. López-Gil JA. Fluconazole-cyclosporine interaction: a dose-dependent effect? Ann Pharmacother. 1993; 27: 427-30.

320. Back DJ, Tjia JF. Comparative effects of the antimycotic drugs ketoconazole, fluconazole, itraconazole and terbinafine on the metabolism of cyclosporin by human liver microsomes. Br J Clin Pharmacol. 1991; 32:624-6. [PubMed 1659439]

321. Kwan JTC, Foxall PJD, Davidson DGC et al. Interaction of cyclosporin and itraconazole. Lancet. 1987; 2:282.

322. Nováková I, Donnelly P, de Witte T et al. Itraconazole and cyclosporin nephrotoxicity. Lancet. 1987; 2:920-1. [IDIS 234636] [PubMed 2889119]

323. Trenk D, Brett W, Jähnchen E et al. Time course of cyclosporin/itraconazole interaction. Lancet. 1987; 2:1335-6.

324. Kramer MR, Marshall SE, Denning DW et al. Cyclosporine and itraconazole interaction in heart and lung transplant recipients. Ann Intern Med. 1990; 113:327-9. [IDIS 270489] [PubMed 2165371]

325. Lindholm A, Henricsson S. Verapamil inhibits cyclosporin metabolism. Lancet. 1987; 1:1262-3. [IDIS 230168] [PubMed 2884392]

326. Maggio TG, Bartels DW. Increased cyclosporine blood concentrations due to verapamil administration. Drug Intell Clin Pharm. 1988; 22:705-7. [IDIS 245365] [PubMed 3063481]

327. Robson RA, Fraenkel M, Barratt LJ et al. Cyclosporin-verapamil interaction. Br J Clin Pharmacol. 1988; 25:402-3. [IDIS 241838] [PubMed 3282534]

328. Sabaté I, Grinó J, Castelao AM et al. Evaluation of cyclosporin-verapamil interaction, with observations on parent cyclosporin and metabolites. Clin Chem. 1988; 34:2151. [IDIS 246875] [PubMed 3168235]

329. Tortorice KL, Heim-Duthoy KL, Awni WM et al. The effects of calcium channel blockers on cyclosporine and its metabolites in renal transplant recipients. Ther Drug Monit. 1990; 12:321-8. [IDIS 269502] [PubMed 2396304]

330. Bourbigot B, Guiserix J, AiriauJ et al. Nicardipine increases cyclosporin blood levels. Lancet. 1986; 1:1447.

331. Todd P, Garioch JJ, Rademaker M et al. Nicardipine interacts with cyclosporin. Br J Dermatol. 1989; 121:820. [IDIS 264139] [PubMed 2611131]

332. Kessler M, Netter P, Renoult E et al. Influence of nicardipine on renal function and plasma cyclosporin in renal transplant patients. Eur J Clin Pharmacol. 1989; 36:637-8. [IDIS 257688] [PubMed 2673796]

333. Sandoz Pharmaceuticals Corporation. Practical guide: Sandimmune (cyclosporine). East Hanover, NJ; 1992 Jul.

334. Ross WB, Roberts D, Griffin PJA et al. Cyclosporin interaction with danazol and norethisterone. Lancet. 1986; 1:330.

335. Interactions

336. Rossi SJ, Schroeder TJ, Hariharan S et al. Prevention and management of the adverse effects associated with immunosuppressive therapy. Drug Safety. 1993; 9:104-31. [PubMed 8397889]

337. Beaufils H, de Groc F, Gubler MC et al. Hemolytic uremic syndrome in patients with Behcet’s disease treated with cyclosporin A: report of 2 cases. Clinical Nephrology ?

338. Katznelson S, Wilkinson A, Rosenthal TR et al. Cyclosporine-induced hemolytic uremic syndrome: factors that obscure its diagnosis. Transplantation Proceedings. 1994; 26:2608-9. [IDIS 337362] [PubMed 7940812]

339. Shulman H, Striker G, Deeg HJ et al. Nephrotoxicity of cyclosporin A after allogeneic marrow transplantation: glomerular thromboses and tubular injury. N Engl J Med. 1981; 305:1392-5. [IDIS 141143] [PubMed 7029278]

340. Sommer BG, Innes JT, Whitehurst RM et al. Cyclosporine-associated renal arteriopathy reulting in loss of allograft function. Am J Surg. 1985; 149:756-64. [IDIS 201270] [PubMed 3893178]

341. Nicholls S, Domizio P, Williams CB et al. Cyclosporin as initial treatment for Crohn’s disease. Arch Dis Child. 1994; 71:243-7. [IDIS 336153] [PubMed 7979499]

342. Camp RDR, Reitamo S, Friedmann PS et al. Cyclosporin A in severe, therapy- resistant atopic dermatitis: report of an international workshop, April 1993. Br J Dermatol. 1993; 129: 217-20. [IDIS 318966] [PubMed 7654593]

343. de Prost Y, Bodemer C, Teillac D. Double-blind randomized placebo-controlled trial of local cyclosporine in atopic dermatitis. Arch Dermatol. 1989; 125:570. [IDIS 254072] [PubMed 2930221]

344. Granlund H, Erkko P, Sinisalo M et al. Cyclosporin in atopic dermatitis: time to relapse and effect of intermittent therapy. Br J Dermatol. 1995: 132:106-12.

345. Munro CS, Higgins EM, Marks JM et al. Cyclosporin A in atopic dermatitis: therapeutic response is dissociated from effects on allergic reactions. Br J Dermatol. 1991: 124:43-8.

346. Ross JS, Camp RDR. Cyclosporin A in atopic dermatitis. Br J Dermatol. 1990; 122(Suppl 36):41-5. [IDIS 268224] [PubMed 2196083]

347. Salek MS, Finlay AY, Luscombe DK et al. Cyclosporin greatly improves the quality of life of adults with severe atopic dermatitis. a randomized, double-blind, placebo-controlled trial. Br J Dermatol. 1993; 129:422-30. [IDIS 320951] [PubMed 8217757]

348. Sepp N, Fritsch PO. Can cyclosporin A induce permanent remission of atopic dermatitis? Br J Dermatol. 1993; 128:213-6.

349. Sowden JM, Berth-Jones J, Ross JS et al. Double-blind, controlled, crossover study of cyclosporin in adults with severe refractory atopic dermatitis. Lancet. 1991; 338:137- 40. [IDIS 283552] [PubMed 1677063]

350. van Joost T, Stolz E, Heule F. Efficacy of low-dose cyclosporine in severe atopic skin disease. Arch Dermatol. 1987; 123:166-7. [IDIS 225170] [PubMed 3813588]

351. van Joost T, Heule F, Korstanje M et al. Cyclosporin in atopic dermatitis: a multicentre placebo-controlled study. Br J Dermatol. 1994: 130:634-40.

352. Lapidoth M, David M, Ben-Amitai D et al. The efficacy of combined treatment with prednisone and cyclosporine in patients with pemphigus: preliminary study. J Am Acad Dermatol. 1994; 30:752-7. [IDIS 329765] [PubMed 8176015]

353. Luisi AF, Stoukides CA. Cyclosporine for the treatment of pemphigus vulgaris. Ann Pharmacother. 1994; 28:1183-5. [IDIS 337078] [PubMed 7841576]

354. Thivolet J, Barthelemy H, Rigot-Muller G et al. Effects of cyclosporin on bullous pemphigoid and pemphigus. Lancet. 1985; 1:334-5. [IDIS 196254] [PubMed 2857378]

355. Gupta AK, Ellis CN, Nickoloff BJ et al. Oral cyclosporine in the treatment of inflammatory and noninflammatory dermatoses. Arch Dermatol. 1990; 126:339-50. [IDIS 265662] [PubMed 2178558]

356. Balato N, De Rosa S, Bordone F et al. Dermatological application of cyclosporine. Arch Dermatol. 1989; 125:1430-1. [IDIS 266478] [PubMed 2535658]

357. Borrego L, Ruiz-Rodriguez R, de Frutos JO et al. Vulvar lichen planus treated with tropical cyclosporine. Arch Dermatol. 1993; 129:794.

358. Eisen D, Griffiths CEM, Ellis CN et al. Cyclosporin wash for oral lichen planus. Lancet. 1990; 335:535-6. [IDIS 264304] [PubMed 1689788]

359. Eisen D, Ellis CN, Duell EA et al. Effect of topical cyclosporine rinse on oral lichen planus: a double-blind analysis. N Engl J Med. 1990; 323:290-4. [IDIS 269487] [PubMed 2195345]

360. Ho VC, Conklin RJ. Effect of topical cyclosporine rinse on oral lichen planus. N Engl J Med. 325:435. Letter.

361. Eisen D, Voorhees JJ. Effect of topical cyclosporine rinse on oral lichen planus. N Engl J Med. 325:435. Letter.

362. Higgins EM, Munro CS, Friedmann PS et al. Cyclosporin A in the treatment of lichen planus. Arch Dermatol. 1989; 125:1436. [IDIS 266480] [PubMed 2802654]

363. Levell NJ, MacLeod RI, Marks JM. Lack of effect of cyclosporin mouthwash in oral lichen planus. Lancet. 1991; 337:796-7. [IDIS 279389] [PubMed 1672422]

364. Levell NJ, Munro CS, Marks JM. Severe lichen planus clears with very low-dose cyclosporin. Br J Dermatol. 1992; 127:66-7. [IDIS 298998] [PubMed 1637703]

365. Pigatto PD, Chiappino G, Bigardi A et al. Cyclosporin A for treatment of severe lichen planus. Br J Dermatol. 1990; 122:121-3. [IDIS 262493] [PubMed 2297500]

366. Porter SR, Scully C, Eveson JW. The efficacy of topical cyclosporin in the managmenet of desquamative gingivitis due to lichen planus. Br J Dermatol. 1993; 129:753-5. [IDIS 323130] [PubMed 8286271]

367. Dougados M, Awada H, Amor B. Cyclosporin in rheumatoid arthritis: a double blind, placebo controlled study in 52 patients. Annals of the Rheumatic Diseases. 1988; 47:127- 33. [IDIS 311752] [PubMed 3281603]

368. Forre O, Bjerkhoel F, Salvesen CF et al. An open, controlled, randomized comparison of cyclosporine and azathioprine in the treatment of rheumatoid arthritis: a preliminary report. Arthritis Rheum. 1987; 30:88-92. [IDIS 228389] [PubMed 3814200]

369. Horton S, Resman-Targoff BH, Thompson DF. Use of cyclosporine in rheumatoid arthritis. Ann Pharmacother. 1993; 27:44-6. [IDIS 307667] [PubMed 8431620]

370. Landewé RBM, Goei Thé HS, van Rijthoven AWAM et al. A randomized, double-blind, 24-week controlled study of low-dose cyclosporine versus chloroquine for early rheumatoid arthritis. Arthritis Rheum. 1994; 37:637-43. [IDIS 330283] [PubMed 8185690]

371. Madhok R, Torley HI, Capell HA. A study of the longterm efficacy and toxicity of cyclosporine A in rheumatoid arthritis. J Rheumatol. 1991; 18: 1485-9.

372. Sigidin YA, Usova SB. Comparative study of cyclosporin A in systemic rheumatoid arthritis. Int J Immunotherapy. 1994; 10:61-5.

373. Tugwell P, Bennett KJ, Chalmers A et al. Low-doe cyclosporin versus placebo in patients with rheumatoid arthritis. Lancet. 1990; 335:1051-5. [IDIS 266064] [PubMed 1970370]

374. van Rijthoven AWAM, Dijkmans BAC, Goei The HS et al. Cyclosporin treatment for rheumatoid arthritis: a placebo controlled, double blind, multicentre study. Annals of the Rheumatic Diseases. 1986; 45:726-31. [IDIS 221834] [PubMed 3532966]

375. Weinblatt ME, Coblyn JS, Fraser PA et al. Cyclosporin A treatment of refractory rheumatoid arthritis. Arthritis Rheum. 1987; 30:11-7. [IDIS 228386] [PubMed 3814192]

376. Yocum DE, Klippel JH, Wilder RL et al. Cyclosporin A in severe, treatment- refractory rheumatoid arthritis: a rnadomized study. Ann Intern Med. 1988; 109:863-9. [IDIS 248225] [PubMed 3190040]

377. Bennett WM. The nephrotoxicity of immunosuppressive drugs. Clinical Nephrology. 1995; 43(Suppl 1):S3-7. [IDIS 344418] [PubMed 7540121]

378. Wadhwa NK, Schroeder TJ, Pesce AJ et al. Cyclosporine drug interactions: a review. Therapeutic Drug Monitoring. 1987; 9:399-406. [IDIS 243009] [PubMed 3321582]

379. Yee GC, McGuire TR. Pharmacokinetic drug interactions with cyclosporin (Part I). Clin Pharmacokinet. 1990; 19:319-32. [PubMed 2208899]

380. Yee GC, McGuire TR. Pharmacokinetic drug interactions with cyclosporin (Part II). Clin Pharmacokinet. 1990; 19:400-15. [PubMed 2268987]

381. Brown AL, Wilkinson R, Thomas TH et al. The effect of short-term low-dose cyclosporin on renal function and blood pressure in patients with psoriasis. Br J Dermatol. 1993; 128:550-5. [IDIS 315656] [PubMed 8504048]

382. Edwards BD, Chalmers RJG, O’Driscoll JB et al. Angiotensin II as a risk factor for cyclosporin nephrotoxicity in patients with psoriasis. 1994; 41:350-6.

383. Feutren G, Friend D, Timonen P et al. Predictive value of cyclosporin A level for efficacy or renal dysfunction in psoriasis. Br J Dermatol. 1990; 122(Suppl 36):85-93. [IDIS 268229] [PubMed 2369572]

384. Feutren G, Abeywickrama K, Friend D et al. Renal function and blood pressure in psoriatic patients treated with cyclosporin A. Br J Dermatol. 1990; 122(Suppl 36):57-69. [IDIS 268226] [PubMed 2196085]

385. Gupta AK, Rocher LL, Schmaltz SP et al. Short-term changes in renal function, blood presure, and electrolyte levels in patients receiving cyclosporine for dermatologic disorders. Arch Intern Med. 1991; 151:356-62. [IDIS 277914] [PubMed 1992963]

386. Korstanje MJ, Bilo HJG, Stoof TJ. Sustained renal function loss in psoriasis patients after withdrawal of low-dose cyclosporin therapy. Br J Dermatol. 1992; 127:501-4. [IDIS 305171] [PubMed 1467290]

387. Pei Y, Scholey JW, Katz A et al. Chronic nephrotoxicity in psoriatic patients treated with low-dose cyclosporine. American Journal of Kidney Diseases. 1994; 23:528-36. [IDIS 329081] [PubMed 8154488]

388. Powles AV, Carmichael D, Hulme B et al. Renal function after long-term low-dose cyclosporin for psoriasis. Br J Dermatol. 1990; 122:665-9. [IDIS 266512] [PubMed 2112945]

389. Powles AV, Cook T, Hulme B et al. Renal function and biopsy findings after 5 years’ treatment with low-dose cyclosporin for psoriasis. Br J Dermatol. 1993; 128:159-65. [IDIS 310349] [PubMed 8457449]

390. International Kidney Biopsy Registry of Cyclosporin A (Sandimmun) in Autoimmune Diseases. Kidney biopsies in control or cyclosporin A-treated psoriatic patients. Br J Dermatol. 1990; 122(Suppl 36):95-100. [IDIS 268230] [PubMed 2369573]

391. Sandoz Pharmaceuticals Corporation. Neoral (cyclosporine for microemulsion) soft gelatin capsules and oral solution prescribing information. East Hanover, NJ; 1995 June.

392. Scott JP, Higenbottam TW. Adverse reactions and interactions of cyclosporin. Medical Toxicology. 1988; 3:107-27. [IDIS 240969] [PubMed 3287088]

393. Tugwell P, Pincus T, Yocum D et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. N Engl J Med. 1995; 333:137-41. [IDIS 349609] [PubMed 7791814]

394. Breedveld FC. New perspectives on treating rheumatoid arthritis. N Engl J Med. 1995; 333:183-4. [IDIS 349613] [PubMed 7791822]

395. Bernstein CN, Shanahan F. Cyclosporine and inflammatory bowel disease: still more questions. Gastroenterology. 1995; 108:943-5. [PubMed 7875503]

396. Feagan BG. Reply. Gastroenterology. 1995; 108:945. [PubMed 7875504]

397. Stange EF, Modigliani R, Pena AS et al. European trial of cyclosporine in chronic active Crohn’s disease: a 12-month study. Gastroentrology. 1995; 109:774-82.

398. Sandborn WJ. Cyclosporine therapy for inflammatory bowel disease: definitive answers and remaining questions. Gastroenterology. 1995; 109:1001-3. [IDIS 353776] [PubMed 7657085]

399. Cooney GF, Mochon M, Kaiser B et al. Effects of carbamazepine on cyclosporine metabolism in pediatric renal transplant recipients. Pharmacotherapy. 1995; 15:353-6. [IDIS 347412] [PubMed 7667170]

400. Ferrari SL, Goffin E, Mourad M et al. The interaction between clarithromycin and cyclosporine in kidney transplant recipients. Trnasplantation. 1994; 58:725-7.

401. Slavin J, Taylor J. Cyclosporin, nifedipine, and gingival hyperplasia. Lancet. 1987; II:739.

402. Gersema LM, Porter CB, Russell EH. Suspected drug interaction between cyclosporine and clarithromycin. Journal of Heart and Lung Transplantation. 1994; 13:343-5. [IDIS 327767] [PubMed 8031821]

403. Gorrie M, Beaman M, Nicholls A et al. Allopurinol interaction with cyclosporin. BMJ. 1994; 308:113. [IDIS 325300] [PubMed 8298381]

404. Stevens SL, Goldman MH. Cyclosporine toxicity associated with allopurinol. South Med J. 1992; 85:1265-6. [IDIS 306883] [PubMed 1470981]

405. Ellis CN, Fradin MS, Hamilton TA et al. Duration of remission during maintenance cyclosporine therapy for psoriasis: relationship to maintenance dose and degree of improvement during initial therapy. Arch Dermatol. 1995; 131:791-5. [IDIS 350435] [PubMed 7611794]

406. Koo J. Cyclosporine in dermatology: fears and opportunities. Arch Dermatol. 1995; 131:842-5. [IDIS 350438] [PubMed 7611807]

407. Kovarik JM, Mueller EA, Johnston A et al. Bioequivalence of soft gelatin capsules and oral solution of a new cyclosporine formulation. Pharmacotherapy. 1993; 13:613-7. [IDIS 322734] [PubMed 8302687]

408. Awni WM, Kasiske BL, Heim-Duthoy K et al. Long-term cyclosporine pharmacokinetic changes in renal transplant recipients: effects of binding and metabolism. Clin Pharmacol Ther. 1989; 45: 41-8. [IDIS 249960] [PubMed 2642778]

409. Kovarik JM, Vernillet L, Mueller EA et al. Cyclosporine disposition and metabolite profiles in renal transplant patients receiving a microemusion formulation. Ther Drug Monitoring. 1994; 16:519-25.

410. Trull AK, Tan KKC, Tan L et al. Absorption of cyclosporin from conventional and new microemulsion oral formulations in liver trnasplant recipients with external biliary diversion. Br J Clin Pharmacol. 1995; 39:627-31. [IDIS 350384] [PubMed 7654480]

411. Trull AK, Tan KKC, Uttridge J et al. Cyclosporin absorption from microemulsion formulation in liver transplant recipient. Lancet. 1993; 341:433. [IDIS 310505] [PubMed 8094190]

412. Sketris IS, McAlister V, Wright MR. Increased cyclosporine bioavailability from a microemulsion formulation in a liver transplant recipient. Ann Pharmacother. 1994; 28:962. [IDIS 334471] [PubMed 7949523]

413. Van den Borne BEEM, Landewé RBM, Goei The HS et al. Relative bioavailability of a new oral form of cyclosporin A in patients with rheumatoid arthritis. BR J Clin Pharmacol. 1995; 39:172-5. [IDIS 342565] [PubMed 7742156]

414. Holt DW, Mueller EA, Kovarik JM et al. Sandimmun Neoral pharmacokinetics: impact of the new oral formulation. Transplantation Proceedings. 1995; 27:1434-7. [IDIS 343892] [PubMed 7878935]

415. Mikhail G, Eadon H, Leaver N et al. Use of Neoral in heart transplant recipients. Transplantation Proceedingsd. 1994; 26:2985-7.

416. Mueller EA, Kovark JM, van Bree JB et al. Influence of a fat-rich meal on the pharmacokinetics of a new oral formulation of cyclosporine in a crossover comparison with the market formulation. Pharmaceutical Research. 1994; 11:151-5. [PubMed 8140046]

417. Kahan BD, Dunn J, Fitts C et al. Reduced inter- and intrasubject variability in cyclosporine pharmacokinetics in renal transplant recipients treated with a microemulsion formulation in conjunction with fasting, low-fat meals, or high-fat meals. Transplantation. 1995; 59:505-11. [IDIS 344578] [PubMed 7878754]

418. Kovarik JM, Mueller EA, van Bree JB et al. Reduced inter- and intraindividual variability in cyclosporine pharmacokinetics from a micoemulsion formulation. Journal of Pharmaceutical Sciences. 1994; 83:444-6. [IDIS 326899] [PubMed 8207699]

419. Kovarik JM, Mueller EA, van Bree JB et al. Cyclosporine pharmacokinetics and variability from a microemulsion formulation: a multicenter investigation in kidney transplant patients. Transplantation. 1994; 58:658-63. [IDIS 337523] [PubMed 7940685]

420. Sketris IS, Gulanikar AC, Methot ME. Cyclosporine-nonsteroidal anti-inflammatory drugs: potential for additive renal dysfunction. Canadian Journal of Hospital Pharmacy. 1992; 45:117-8.

421. Branthwaite JP, Nicholls A. Cyclosporin and diclofenac interaction in rheumatoid arthritis. Lancet. 1991; 337:252. [IDIS 276806] [PubMed 1670893]

422. Mueller EA, Kovarik JM, van Bree JB et al. Improved dose linearity of cyclosporine pharmacokinetics from a microemulsion formulation. Pharmaceutical Research. 1994; 11:301-4. [PubMed 8165192]

423. Friman S, Bäckman L. A new microemulsion formulation of cyclopsorin: pharmacokinetic and clinical features. Clin Pharmacokinet. 1996; 30:181-93. [PubMed 8882300]

424. Holt DW, Johnston A, Roberts NB et al. Methodological and clinical aspects of cyclosporin monitoring: report of the Association of Clinical Biochemists task force. Ann Clin Biochem. 1994; 31:420-46. [PubMed 7832569]

425. Lindholm A. Factors influencing the pharmacokinetics of cyclosproine in man. Ther Drug Monitor. 1991; 13:465-77.

426. Yee GC, Mills G, Shaffer R et al. Renal cyclosporine clearance in marrow transplant recipients: age-related variation. J Clin Pharmacol. 1986; 26:658-61. [IDIS 222643] [PubMed 3540031]

427. Ptachcinski RJ, Burckart GJ, Rosenthal JT et al. Cyclosporine pharmacokinetics in children following cadaveric renal transplantation. Transplant Proc. 1986; 18:766-7.

428. Yee GC, Lennon TP, Gmur DJ et al. Age-dependent cyclosporine: pharmacokinetics in marrow transplant recipients. Clin Pharmacol Ther. 1986; 40:438-43. [IDIS 222130] [PubMed 3530588]

429. Roche. Posicor (mibefradil hydrochloride) tablets prescribing information. Nutley, NJ; 1997 Dec.

430. Ellison RH. Dear doctor letter regarding appropriate use of Posicor. Nutley, NJ: Roche Laboratories; 1997 Dec.

431. Sandoz. Neoral (cyclosporine for microemulsion) soft gelatin capsules and oral solution prescribing information. East Hanover, NJ; 1997 Jun.

432. Yee GC, Stanley DL, Pessa LJ et al. Effect of grapefruit juice on blood cyclosporin concentration. Lancet. 1995; 345:955-6. [IDIS 346003] [PubMed 7715295]

433. Hollander AAMJ, van Rooij J, Lentjes EGWM et al. The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients. Clin Pharmacol Ther. 1995; 57:318-24. [IDIS 345088] [PubMed 7697949]

434. Bailey DG, Arnold JMO, Spence JD. Grapefruit juice and drugs: how significant is the interaction? Clin Pharmacokinet. 1994; 26:91-8.

435. Cyclosporine/food (grapefruit juice). In: Tatro DS, Olin BR, Hebel SK eds. Drug interaction facts. St. Louis: JB Lippincott Co; 1996(July):233b.

436. Midazolam (Versed) interactions: grapefruit juice. In: Hansten PD, Horn JR. Drug interactions and updates. Vancouver, WA: Applied Therapeutics, Inc; 1996:932.

437. Merkel U, Sigusch H, Hoffmann A. Grapefruit juice inhibits 7-hydroxylation of coumarin in healthy volunteers. Eur J Clin Pharmacol. 1994; 46:175-7. [IDIS 328458] [PubMed 8039540]

438. Proppe DG, Hoch OD, McLean AJ et al. Influence of chronic ingestion of grapefruit juice on steady-state blood concentrations of cyclosporine A in renal transplant patients with stable graft function. Br J Clin Pharmacol. 1995; 39:337-8. [IDIS 344573] [PubMed 7619679]

439. Soons PA, Vogels BAPM, Roosemalen MCM et al. Grapefruit juice and cimetidine inhibit stereoselective metabolism of nitrendipine in humans. Clin Pharmacol Ther. 1991; 50:394-403. [IDIS 289421] [PubMed 1914375]

440. Fuhr U, Klittich K, Staib AH. Inhibitory effect of grapefruit juice and its bitter principal, naringenin, on CYP1A2 dependent metabolism of caffeine in man. Br J Clin Pharmacol. 1993; 35:431-6. [IDIS 313857] [PubMed 8485024]

441. Bailey DG, Spence JD, Munoz C et al. Interaction of citrus juices with felodipine and nifedipine. Lancet. 1991; 337:268-9. [IDIS 277404] [PubMed 1671113]

442. Campana C, Regazzi MB, Buggia I et al. Clinically significant drug interactions with cyclosporin: an update. Clin Pharmacokinet. 1996; 30:141-179. [PubMed 8906896]

443. Kupferschmidt HHT, Ha HR, Ziegler WH et al. Interaction between grapefruit juice and midazolam in humans. Clin Pharmacol Ther. 1995; 58:20-8. [IDIS 351225] [PubMed 7628179]

444. Sandoz Pharmaceuticals Corp. Neoral (cyclosporine for microemulsion) soft gelatin capsules and oral solution prescribing information. East Hanover, NJ; 1995 Sep.

445. Johnston A, Holt DW. Effect of grapefruit juice on blood cyclosporin concentration. Lancet. 1995; 346:122-3. [IDIS 351709] [PubMed 7603196]

446. Hollander AAMJ, van der Woude FJ, Cohen AF. Effect of grapefruit juice on blood cyclosporin concentration. Lancet. 1995; 346:123. [IDIS 351710] [PubMed 7677856]

447. Yee GC, Lowenthal DT. Effect of grapefruit juice on blood cyclosporin concentration. Lancet. 1995; 346:123-4. [IDIS 351710] [PubMed 7677856]

448. Ameer B, Weintraub RA, Johnson JV et al. Flavanone absorption after naringin, hesperidin, and citrus administration. Clin Pharmacol Ther. 1996; 60:34-40. [PubMed 8689809]

449. Edwards DJ, BellevueFH, Woster PM. Identification of 6′,7′-dihydroxybergamottin, a cytochrome P-450 inhibitor in grapefruit juice. Drug Metabol Dispos. (in press)

450. Edwards DJ, Bernier SM. Naringin and naringenin are not the primary CYP3A inhibitors in grapefruit juice. Life Sci. 1996; 59:1025-30. [PubMed 8809221]

451. Lundahl J, Regardh CG, Edgar B et al. Relationship between time of intake of grapefruit juice and its effect on pharmacokinetics and pharmacodynamics of felodipine in healthy subjects. Eur J Clin Pharmacol. 1995; 49:61-7. [IDIS 357628] [PubMed 8751023]

452. Ameer B, Weintraub RA. Drug interactions with grapefruit juice. Clin Pharmacokinet. 1997; 33:103-21. [PubMed 9260034]

453. Ducharme MP, Warbasse LH, Edwards DJ. Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. Clin Pharmacol Ther. 1995; 57:485-91. [IDIS 348369] [PubMed 7768070]

454. Hukkinen SK, Varhe A, Olkkola KT et al. Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice. Clin Pharmacol Ther. 1995; 58:127-31. [IDIS 352452] [PubMed 7648762]

455. Anon. Grapefruit juice interactions with drugs. Med Lett Drugs Ther. 1995; 37:73-4. [PubMed 7630329]

456. Zachariae H, Kragballe K, Hansen HE et al. Renal biopsy findings in long-term cyclosporin treatment of psoriasis. Br J Dermatol. 1997; 136:531-5. [IDIS 384784] [PubMed 9155953]

457. Edwards BD, Bhatnagar D, Mackness MI et al. Effect of low-dose cyclosporin on plasma lipoproteins and markers of cholestasis in patients with psoriasis. Q J Med. 1995; 88:109-13.

458. Berth-Jones J, Voorhees JJ. Consensus conference on cyclosporin A microemulsion for psoriasis, June 1996. Br J Dermatol. 1996; 135:775-7. [IDIS 376451] [PubMed 8977680]

459. Grossman RM, Maugee E, Dubertret L. Cervical intraepithelial neoplasia in a patient receiving long-term cyclosporin for the treatment of severe plaque psoriasis. Br J Dermatol. 1996; 135:147-8. [IDIS 370504] [PubMed 8776385]

460. Altman RD, Perez GO, Sfakianakis GN. Interaction of cyclosporine A and nonsteroidal anti-inflammatory drugs on renal function in patients with rheumatoid arthritis. Am J Med. 1992; 93:396-402. [IDIS 303624] [PubMed 1415303]

461. Kovarik JM, Kurki P, Mueller E et al. Diclofenac combined with cyclosporine in treatment refractory rheumatoid arthritis: longitudinal safety assessment and evidence of a pharmacokinetic/dynamic interaction. J Rheumatol. 1996; 23:2033-8. [IDIS 378913] [PubMed 8970037]

462. Kovarik JM, Mueller EA, Gerbeau C et al. Cyclosporine and nonsteroidal antiinflammatory drugs: exploring potential drug interactions and their implications for the treatment of rheumatoid arthritis. J Clin Pharmacol. 1997; 37:336-43. [IDIS 385759] [PubMed 9115060]

463. Lowe NJ, Wieder JM, Rosenbach A et al. Long-term low-dose cyclosporine therapy for severe psoriasis: effects on renal function and structure. J Am Acad Dermatol. 1996; 35:710-9. [IDIS 376229] [PubMed 8912566]

464. Ad Hoc Committee on Clinical Guidelines, American College of Rheumatology. Guidelines for monitoring drug therapy in rheumatoid arthritis. Arthritis Rheum. 1996; 39:723-31. [IDIS 367465] [PubMed 8639168]

465. Tugwell P, Ludwin D, Gent M et al. Interaction between cyclosporin A and nonsteroidal antiinflammatory drugs. J Rheumtol. 1997; 24:1122-5.

466. Grossman RM, Chevret S, Abi-Rached J et al. Long-term safety of cyclosporine in the treatment of psoriasis. Arch Dermatol. 1996; 132:623-9. [IDIS 368726] [PubMed 8651712]

467. Rodriguez F, Krayenbuhl JC, Harrison WB et al. Renal biopsy findings and followup of renal function in rheumatoid arthritis patients treated with cyclosporin A: an update from the International Kidney Biopsy Registry. Arthritis Rheum. 1996; 39:1491-8. [IDIS 373609] [PubMed 8814060]

468. Feutren G, Mihatsch MJ. Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. N Engl J Med. 1992; 326:1654-60. [IDIS 298102] [PubMed 1588978]

469. Landewe RBM, Dijkmans BAC, van der Woude FJ et al. Longterm low dose cyclosporine in patients with rheumatoid arthritis: renal function loss without stuctural nephropathy. J Rheumatol. 1996; 23:61-4. [IDIS 358263] [PubMed 8838509]

470. Pei Y. Chronic cyclosporine nephrotoxicity in rheumatoid arthritis. J Rheumtol. 1996; 23:4-5.

471. Ludwin D, Alexopoulou I, Esdaile JM et al. Renal biopsy specimens from patients with rheumatoid arthritis and apparently normal renal function after therapy with cyclosporine. Am J Kid Dis. 1994; 23:260-5. [IDIS 32558] [PubMed 8311085]

472. Sund S, Forre O, Berg KJ et al. Morphological and functional renal effects of long- term low-dose cyclosporin A treatment in patients with rheumatoid arthritis. Clin Nephrol. 1994; 41:33-40. [IDIS 325400] [PubMed 8137567]

473. Pasero G, Priolo F, Marubini E et al. Slow progression of joint damage in early rheumatoid arthritis treated with cyclosporin A. Arthritis Rheum. 1996; 39:1006-15. [IDIS 368499] [PubMed 8651963]

474. Shupack J, Abel E, Bauer E et al. Cyclosporine as maintenance therapy in patients with severe psoriasis. J Am Acad Dermatol. 1997; 36:423-32. [IDIS 385904] [PubMed 9091474]

475. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum. 2002; 46:328-46. [IDIS 476480] [PubMed 11840435]

476. Abbott Laboratories. Gengraf (cyclosporine) capsules, USP (modified), prescribing information. North Chicago, IL; 2009 Jun.

477. Abbott Laboratories. Gengraf (cyclosporine) oral solution, USP (modified), prescribing information. North Chicago, IL; 2009 Jun.

478. Novartis Pharmaceuticals Corporation. Neoral (cyclosporine) soft gelatin capsules, USP (modified), and oral solution, USP (modified), prescribing information. East Hanover, NJ; 2009 Mar.

479. Novartis Pharmaceuticals Corporation. Sandimmune (cyclosporine) soft gelatin capsules, oral solution, and injection prescribing information. East Hanover, NJ; 2008 June.

480. Food and Drug Administration. Electronic Orange Book. From FDA website (). Accessed 4 Jan 2006.

481. Carnahan W, Cooper TY. Neoral-to-Gengraf conversion in renal transplant recipients. Transplant Proc. 2003; 35:1308-13. [IDIS 499522] [PubMed 12826145]

482. Roza A, Tomlanovich S, Merion R et al. Conversion of stable renal allograft recipients to a bioequivalent cyclosporine formulation. Transplantation. 2002; 74:1013-7. [IDIS 489309] [PubMed 12394847]

483. Abbott Laboratories, North Chicago, IL: Personal communication.

484. Hanauer SB, Sandborn W, and the Practice Parameters Committee of the American College of Gastroenterology. Management of Crohn’s disease in adults: Practice Guidelines. Am J Gastroenterol. 2001; 96:635-43. [IDIS 461432] [PubMed 11280528]

485. Scribano M, Pantera C. Review article: medical treatment of moderate to severe Crohn’s disease. Aliment Pharmacol Ther. 2003; 17 (Suppl. 2):23-30. [PubMed 12786609]

486. Hanauer SB, Present DH. The state of the art in the management of inflammatory bowel disease. Rev Gastroenterol Disord. 2003; 3:81-92. Selby WS. Current issues in Crohn’s disease. Rev Gastroenetrol Disord. 2003; 3:81-92.

487. Hanauer SB. Inflammatory bowel disease. N Engl J Med. 1996; 334:841-8. [IDIS 361805] [PubMed 8596552]

488. Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002; 347:417-29. [IDIS 484721] [PubMed 12167685]

489. Cat H, Sophani I, Lemann M, Modiglani R et al. Cyclosporin treatment of anal and perianal lesions associated with Crohn’s disease. Turk J Gastroenterol. 2003; 14: 121-7. [PubMed 14614639]

490. Haslam N, Hearing SD, Probert CS. Audit of cyclosporin use in inflammatory bowel disease: limited benefits, numerous side-effects. Eur J Gastroenterol Hepatol. 2000; 12:657-60. [PubMed 10912486]

491. Löfberg R. Review article: medical treatment of mild to moderately active Crohn’s disease. Aliment Pharmacol Ther. 2003; 17 (Suppl 2):18-22.

492. Egan LJ, Sandborn WJ, Tremaine WJ. Clinical outcome following treatment of refractory inflammatory and fistulizing Crohn’s disease with intravenous cyclosporine. Am J Gastroenterol. 1998; 93: 442-8. [PubMed 9517654]

493. Korelitz BI, Adler DJ, Mendelsohn RA et al. Long-term experience with 6-mercaptopurine in the treatment of Crohn’s disease. Am J Gastroenterol.1993; 88:1198-205. [IDIS 318335] [PubMed 8338087]

494. Present DH, Korelitz BI, Wisch N et al. Treatment of Crohn’s disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med. 1980; 302: 981-7. [IDIS 113855] [PubMed 6102739]

584. Food and Drug Administration. Information for healthcare professionals: immunosuppressant drugs, required labeling changes [sirolimus (marketed as Rapamune), cyclosporine (marketed as Sandimmune and generics), cyclosporine modified (marketed as Neoral and generics), mycophenolate mofetil (marketed as Cellcept and generic), mycophenolic acid (marketed as Myfortic)]. Rockville, MD; July 14, 2009. From FDA website http: / / www.fda.gov / Drugs / DrugSafety / PostmarketDrugSafetyInformationforPatientsandProviders / DrugSafetyInformationforHeathcareProfessionals / ucm171654.htm.

585. Wiseman AC. Polyomavirus nephropathy: a current perspective and clinical considerations. Am J Kidney Dis. 2009; 54:131-42. [PubMed 19394729]

586. Bonvoisin C, Weekers L, Xhignesse P et al. Polyomavirus in renal transplantation: a hot problem. Transplantation. 2008; 85 (suppl 7):S42-8.

587. Mannon RB. Polyomavirus nephropathy: what have we learned?. Transplantation. 2004; 77:1313-8. [PubMed 15167583]

588. Ziedina I, Folkmane I, Chapenko S et al. Reactivation of BK Virus in the Early Period After Kidney Transplantation. Transplant Proc. 2009; 41:766-8. [PubMed 19328975]

589. Dharnidharka VR, Cherikh WS, Abbott KC. An OPTN analysis of national registry data on treatment of BK virus allograft nephropathy in the United States. Transplantation. 2009; 87:1019-26. [PubMed 19352121]

590. Alméras C, Foulongne V, Garrigue V et al. Does reduction in immunosuppression in viremic patients prevent BK virus nephropathy in de novo renal transplant recipients? A prospective study. Transplantation. 2008; 85:1099-104. [PubMed 18431228]

591. Hirsch HH, Brennan DC, Drachenberg CB et al. Polyomavirus-associated nephropathy in renal transplantation: interdisciplinary analyses and recommendations. Transplantation. 2005; 79:1277-86. [PubMed 15912088]

592. Benavides CA, Pollard VB, Mauiyyedi S et al. BK virus-associated nephropathy in sirolimus-treated renal transplant patients: incidence, course, and clinical outcomes. Transplantation. 2007; 84:83-8. [PubMed 17627242]

593. Actelion Pharmaceuticals. Tracleer (bosentan) tablets prescribing information. South San Francisco, CA; 2009 Aug.

594. Novartis Pharmaceuticals Corporation. Neoral (cyclosporine) soft gelatin capsules, USP (modified), and oral solution, USP (modified), prescribing information. East Hanover, NJ; 2009 Oct.

595. Novartis Pharmaceuticals Corporation. Sandimmune (cyclosporine) soft gelatin capsules, oral solution, and injection prescribing information. East Hanover, NJ; 2009 Oct.

a. Fujisawa USA, Inc. Prograf (tacrolimus) prescribing information. Deerfield, IL; 2003 Aug.

HID. Trissel LA. Handbook on injectable drugs. 17th ed; Bethesda, MD: American Society of Health-System Pharmacists; 2013:319-21.

Hide
(web1)